

MARY LENORA (NORA) DISIS, MD, FACP
Curriculum Vitae

Personal Data:

Place of Birth: Chicago, IL

Citizenship: United States

Education:

1981 B.S., Creighton University, Omaha, NE, Dual major: Chemistry and English

1986 M.D. / M.S. (Immunology), University of Nebraska, Omaha, NE

Postgraduate Training:

1986-1989 Internship and Residency in Internal Medicine, University of Illinois, Chicago, IL

1989-1990 Chief Resident in Internal Medicine, University of Illinois, Chicago, IL

1990-1993 Senior Oncology Fellow, University of Washington (UW), Seattle, WA

Faculty Positions:

1989-1990 Instructor, Department of Medicine, University of Illinois, Chicago, IL

1993-1994 Acting Instructor, Division of Oncology, UW, Seattle, WA

1994-1999 Assistant Professor, Division of Oncology, UW, Seattle, WA

1998-2004 Director, Tumor Vaccine Group, UW, Seattle, WA

1999-2006 Associate Professor, Division of Oncology, UW, Seattle, WA

2001-2006 Associate Member, Clinical Division, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA

2004-present Director, Center for Translational Medicine in Women's Health, UW, Seattle, WA

2004-2008 Director, General Clinical Research Center, UW, Seattle, WA

2005-2006 Adjunct Associate Professor, Pathology, UW, Seattle, WA

2006-present Professor, Division of Oncology, UW, Seattle, WA

2006-present Member, Clinical Division, FHCRC, Seattle, WA

2006-present Adjunct Professor, Obstetrics and Gynecology, UW, Seattle, WA

2006-present Adjunct Professor, Pathology, UW, Seattle, WA

2007-present Associate Dean for Translational Science, UW School of Medicine, Seattle, WA

2007-present Director, Institute for Translational Health Sciences, UW, Seattle, WA

Hospital Positions Held:

1993-1994 Staff Physician, VA Puget Sound Health Care System, Seattle Division

1994-present Staff Physician, University of Washington Medical Center

2001-2008 Staff Physician, Seattle Cancer Care Alliance

Honors:

Spirit of Creighton Award, 1981

Michaelson Scholarship for Research in Cystic Fibrosis, 1984, 1985

IOTA Benefit Association Research Award, 1984

Intern of the Year, University of Illinois, 1987

Alpha Omega Alpha, University of Illinois College of Medicine, 1989

Clinical Oncology Fellowship, American Cancer Society, 1990-1991

Upjohn Outstanding Oncology Fellow Award, University of Washington, 1991

Berlex Oncology Foundation Clinical Research Fellow, 1993-1995

ACS Physician Research Training Award, 1994-1996

Clinical Investigator Award, National Cancer Institute, 1995-2000

FIRST Award, National Cancer Institute, 1995-2000

Science in Medicine, New Investigator Lectureship, University of Washington College of Medicine, 1995

Mid-Career Investigator Award in Patient Oriented Research, National Cancer Institute. 2000-2005

Science in Medicine Lectureship, University of Washington College of Medicine, 2001

University of Washington School of Medicine/Center of Women's Health Award for Outstanding Mentorship, 2003

Olympic Medical Center Foundation Celebrating Hope Award for Scientific Achievement, 2003

Elected, American Society of Clinical Investigation (ASCI), 2004

Chair, Clinical Oncology Study Section (CONC), NIH/NCI, 2004-2006

2006 Science Forum Lecturer, University of Washington, College of Arts and Sciences

Elected, Board of Directors, International Society of Biologic Therapy, 2006-2009

Cancer Treatment Research Foundation Award for Scientific Excellence, 2006

Scholarship, American Association of Medical Schools Women's Faculty Seminar, 2007

Elected, Fellow, American College of Physicians, 2008

Recipient, Kroc Endowed Lectureship, University of South Carolina, Department of Microbiology and Immunology, 2009

Team Science Award, International Society of Biologic Therapy, 2010

Elected, Association of American Physicians (AAP), 2011

Recipient, Merrill Egorin Award for Mentoring, 2012, ASCO-AACR

Komen Foundation Scholar, 2012-2018

Recipient, Athena Distinguished Professorship of Breast Cancer Research, 2013-present

Appointed, University of Washington Presidential Innovation Fellow, 2013-2015

Recipient, 2013 Frederic C. Bartter Professor in Clinical Investigation at the University of Texas (UT) Health Science Center at San Antonio

American Cancer Society Clinical Professor, 2015-2020

ASCO Fellow, 2016

Board Certification:

1989 American Board of Internal Medicine

1997, 2008 Sub-specialty Board in Medical Oncology

Current License to Practice:

1990-present Washington

U.S. Patents, International Patents, and Patent Applications:

U.S. Patent #5,801,005: Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated.

U.S. Patent # 5,869,445: Methods for eliciting or enhancing reactivity to HER-2/neu protein.

U.S. Patent # 5,726,023: Immune reactivity to HER-2/neu protein for diagnosis.

US Patent # 5,846,538: Methods and compositions to generate immunity in humans against self-tumor antigens by immunization with homologous foreign proteins.

U.S. Patent #5,876,712. T cell therapy directed against HER-2/neu protein.

U.S. Patent #8,524,491 B2. Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated.

U.S. Patent #6,180,114. Therapeutic delivery using compounds self-assembled into high axial ratio microstructures.

US Patent #7,247,703: Immune reactivity to Her-2/neu protein for diagnosis and treatment of malignancies in which the Her-2/neu oncogene is associated

U.S. Patent #7,547,681: Surface receptor antigen vaccines.

U.S. Patent #9,060,961: Molecules and methods for the treatment and detection of cancer

U.S. Patent #8216789: Panel of serum autoantibodies for breast cancer diagnosis

U.S. Patent Application #15/300,208: Breast and ovarian cancer vaccines

U.S. Patent Application #61031836: Diagnostic panel of oncogenic proteins and methods for use

U.S. Patent Application #12/740,562: HLADR binding peptides and their uses

U.S. Patent Application #15/300, 257: Methods of identifying antigens for vaccines

U.S. Provisional Patent Application #62026246: Compositions of colorectal cancer vaccines

U.S. Patent Application #61/968,961: Methods of cancer diagnosis, prognosis and treatment

U.S. Patent Application #62/146,601: Epidermal growth factor receptor 1 derived multi-peptide compositions and uses thereof

U.S. Patent Application #PC/US2016/046816: Methods and materials for expanding antigen specific T-cells in culture

Investigational New Drug Applications

BB IND 6524: A Phase I Study of a HER-2/neu Peptide Based Vaccine with GM-CSF as an Adjuvant in Patients with Advanced Stage HER-2/neu Expressing Cancers

BB IND 7917: A Phase I Study of a HER-2/neu Peptide-Based Vaccine with Flt3 Ligand or GM-CSF as an Adjuvant in Patients with Advanced Stage Prostate Cancer

BB IND 8909: A Phase I Study of a HER-2/neu Intracellular Domain (HER2 ICD) Protein and GM-CSF as Adjuvant in Patients with HER-2 -Expressing Breast or Ovarian Cancer

BB IND 11532: A Phase I Trial to Evaluate the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the HER-2/neu Intracellular Domain in Subjects with Her-2/neu (HER2) Overexpressing Tumors

BB IND 11766: A Phase I Study of Infusion of HER-2/neu Specific T Cells in Patients with Advanced Stage HER-2/neu Expressing Cancers who have Received a HER-2/neu Vaccine

BB IND 14906: A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients with Advanced Ovarian Cancer

BB IND 16249: A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients

Professional Organizations:

Alpha Omega Alpha (AOA)

American Association for Cancer Research (AACR)

American Association of Immunologists (AAI)

American Society of Clinical Investigation (ASCI)

American Society for Clinical Oncology (ASCO)
American Society of Hematology (ASH)
Society for Immunotherapy of Cancer (SITC)
Southwest Oncology Group (SWOG)
Association for Clinical and Translational Science (ACTS)

Teaching Responsibilities

a. University of Washington

1994-1996	Director, Oncology Board Review Course
1996-1998	Lecturer for Pathobiology 580 Seminar
1996-present	Mentor for the STAR Program for training minority students for a career in research
1999-2004	Oncology Lectures Quarterly, UW Medicine Resident's Teaching Conference
2001-present	Speaker, High School Science Students Visitor Program, UW
2003	Speaker, Howard Hughes Outreach Program for Community College Faculty in the Life Sciences
2005, 2006	Lecturer for Pathology 514

b. Continuing Medical Education

1995-1998	Hematology/Oncology Grand Rounds, UW
1998, 1999, 2001, 2003	UW, CME, Breast Cancer Update
1999, 2002	Swedish Hospital, CME, Novel Cancer Therapeutics
1999	Denali Oncology CME Conference, Haines, AK
1999, 2001, 2004, 2007	Medical Grand Rounds, University of Washington
2003	Dermatology Grand Rounds, University of Washington
2008	Medical Grand Rounds, University of Washington
2008	Neurosurgery Grand Rounds, University of Washington
2016	Radiology Grand Rounds, University of Washington

c. Mentorship of Trainees

Postdoctoral Fellows

1996-1998 Bradley Stone, Ph.D., current: Staff Scientist, University of Washington, Seattle, WA

1997-2000 Douglas G. McNeel, M.D., Ph.D., current: Professor, University of Wisconsin, Madison, WI

1998-2000 Kristine Rinn, M.D., current: Member, Breast Program, Swedish Tumor Institute, Seattle, WA

1998-2000 Arianna Smorlesi, Ph.D., current: Research Scientist, Dip. Ricerche INRCA, Ancona, Italy

1998-2001 Keith L. Knutson, Ph.D., current: Professor, Mayo Clinic, Jacksonville, FL

2000-2003: Lupe G. Salazar, M.D., current: Associate Professor, UW

2001-2004: Bond Almand, M.D.; current: ENT Practice, VA

2001-2003: Carmen Berger, M.D.; current: Dermatology Practice, WA

2003-2004: Amy Jan, M.D., Ph.D., current: Dermatology Practice, CA

2003-2005 Wolfgang Wagner, Ph.D., current: Scientist in biotech industry

2003-2006 Hailing Lu, PhD, current: Senior Scientist, Immune Design, Seattle, WA

2004-2006 Devon Webster, M.D., current: Hematology/Oncology Practice, OR

2004-2006 Mohamed El-Sayed, Ph.D., current: Associate Professor, University of Michigan, Ann Arbor, MI

2005-2010 Vy P. Lai, Ph.D., current: Scientific consultant

2005-2007: Kyong Park, M.D., Ph.D., current: Associate Professor, Korea University, Seoul, Korea

2005-2009 Andrew Coveler, M.D., current: Associate Professor, UW

2007-2010 Gregory Holt, M.D., Ph.D., current: Assistant Professor, University of Miami

2008-2013 Denise Cecil, PhD, current: Research Scientist, Tumor Vaccine Group

2009-2012 Elizabeth Broussard, M.D., Assistant Professor, UW

2009-2011 Jianning Mao, PhD, current: Scientific consultant

2009-2011 Megan O'Meara, MD, current: Medical Director, Seattle Genetics

2010-2011 Jong-Baeck Lim, M.D., current: Assistant Professor, Seoul Korea

2010-2015 John Liao, MD, Assistant Professor, Tumor Vaccine Group

2012-2013	Edmond Marzbani, MD, PhD. Current: Assistant Professor, University of Washington
2012-2016	Juan Pablo Marquez-Manriquez, MD, PhD, Visiting Scientist, Tumor Vaccine Group
2013-present	Sasha Stanton, MD, PhD, Acting Instructor, University of Washington
2014-2015	Gregory Cherryholmes, PhD, Current, Scientist in the Biotech Industry
2014-present	Laura Riobos, PhD, Acting Instructor, Tumor Vaccine Group
2014-2015	Zina Rutman, PhD, Current, Scientist in Biotech Industry
2015-present	Marc Lajoie, PhD, Post-Doctoral Fellow, Tumor Vaccine Group
2016-present	Will Gwin, MD, Acting Instructor, Tumor Vaccine Group

Graduate Students, Medical Students and Undergraduates

1996-1998	Catherine Carr, M.D.: Project: Immunity to lung cancer related proteins (graduated to Pediatric Residency, UW)
1997	Quan Chen: Project: Serologic diagnosis of DCIS (graduated to OHSU Medical School)
2001-2003	Travis Widman, M.D.: Project: Safety and toxicity of DNA vaccines in a murine model (graduated to Stanford University Dermatology Residency)
2001-2004	Vivian Goodell: Master's Thesis Project: Antibody immunity to p53 and HER-2/neu as an ovarian cancer diagnostic and prognostic test (current: Research Scientist, UCSD)
2003-2005	Jason Lukas, M.D.: Project: Role of T regulatory cells in inhibiting immunity (graduated to Oncology Fellowship, UCSF)
2005-2006	Amy Chang: Undergraduate research project on discovery of homologous breast cancer antigens between human and mouse.
2006	Megan O'Meara, MD: Project: Development of PCR based assay for T regulatory cells (graduated to Oncology fellowship, UW)
2006	John Strickler, MD: Project: In vivo augmentation of adoptively transferred T cells (graduated to Oncology fellowship, Duke University)

- 2006 Helena Tufvesson: Project: Identification of novel tumor antigens (Swedish exchange student)
- 2008 William Gwin, MD: Project: In vivo manipulation of the tumor specific T cell response with epidermal Langerhan's cell growth factors (graduated to Oncology Fellowship, Duke University)
- 2008 Edmond Marzbani, MD, PhD: Identification of antibody biomarkers for cancer diagnosis (graduated to Oncology Fellowship, UW)
- 2008 Paramita Mukherjee, MD, PhD: Performance characteristics of ELISPOT (UW medicine resident)
- 2008 Priya Rao, MD: Autoreactivity after vaccination to "self" tumor antigens with a DNA vaccine (UW medicine resident)
- 2008 Kelly Garneski Paulson: PhD Candidate, Member of Supervisory Committee
- 2009 Jonathan M. Keller: Medical Student Training Program. Project: Phase I study of adoptive T cell therapy.
- 2015-2016 Elliot Hershberg: Project: Measuring immune responses in murine models (undergraduate, Southwestern University, TX).

Editorial Responsibilities

A. Journals

- Editor-in-Chief, JAMA Oncology, 2014-present
- Editorial Board, JAMA, 2014-present
- Deputy Editor, Journal of Clinical Oncology, 2006-2014
- Associate Editor, Journal for ImmunoTherapy of Cancer, 2012-2014
- Advisory Board, Science Translational Medicine, 2009-2014
- Editorial Academy of the International Journal of Oncology, 2008-2014
- Editorial Board, Molecular Cancer Therapeutics, 2006-2012
- Editorial Board, Journal of Immunotherapy, 2007-2012
- Editorial Board, Journal of Translational Medicine, 2007-2013
- Editorial Board, Cancer Immunology and Immunotherapy, 2007-2013
- Editorial Board, Update on Cancer Therapeutics, 2005-2014
- Editorial Board, Cancer Immunology Research, 2013-2014

B. Books

Editor, Hematology/Oncology Clinics of North America, Ovarian Cancer, 2003

Editor, Immunotherapy of Cancer, Humana Press, 2005

Special National Responsibilities:

1996-1998 Visiting Professor in Immunology, Shanghai Medical University, Shanghai, PRC

1998-2003 Chair, Immunomolecular Therapeutics Committee, SWOG

1999-2002 Course Director, *Immunology*, National Breast Cancer Coalition, Project LEAD

1999-2003 Course Director, *Genetics in Cancer*, Berlex Oncology Foundation

1999-2001 Member, Berlex Oncology Foundation Board of Trustees

2001-present Member, Cancer Education Consortium (CEC) Board of Trustees

2000-2002 Member, Integration Panel, Department of Defense Breast Cancer Program

2001 Member, Gynecologic Cancer Progress Review Group (PRG), NCI

2001 Chair, Immunology and Immunotherapy Round-Table, Gynecologic Cancer PRG, NCI

2001-2005 Member, CTEP/NCI, Cancer Vaccines Working Group

2001-2004, Faculty Member, Annual ASCO/AACR Clinical Trials Workshop

2001 Member, Steering Committee, Workshop on Immunologic Monitoring for Cancer Immunotherapy, Society of Biologic Therapy, CTEP, FDA

2002-2005 Chair, Grantsmanship Workshop, AACR Annual Meeting

2002-2004 Member, NCI Biological Resources Branch Oversight Committee

2002 Member, Organizing Committee, DOD Breast Cancer Program, *Era of Hope* Meeting

2002-2006 Member, ASCO Program Committee

2003 Member, Immunology Subcommittee, Program Committee, AACR Annual Meeting

2003-2012 Member, Cancer Immunology and Immunotherapy Task Force, AACR

2003 Track Leader, ASCO Program Committee for Developmental Therapeutics-Immunotherapy

2003-2006 Member, ASCO Cancer Education Committee

2003-2005 Co-Chair, Immunomolecular Therapeutics Committee, SWOG

2003-2012 Course Director, *Molecular Oncology and Clinical Translation*, CEC

2003-2005 Scientific Advisory Board, Human Immune Therapy Center, University of Virginia

2003-2005 Member, Program Committee, Annual ASCO/AACR Clinical Trials Workshop

- 2004 Member, Clinical Research Subcommittee, Program Committee, AACR Annual Meeting
- 2004 Member, Experimental and Molecular Therapeutics Subcommittee, Program Committee, AACR Annual Meeting
- 2004-2009 Member, External Advisory Committee, Duke University Breast Cancer Program
- 2004-2007 Member, Organizing Committee, 7th AACR/Japanese Cancer Association Joint Conference
- 2004 Member, Steering Committee, Workshop on Immunologic Monitoring for Cancer Immunotherapy, Society of Biologic Therapy, CTEP, FDA
- 2004-2005 Vice-Chair, ASCO Cancer Education Committee
- 2004 Chair, 2004-2005 Nominating Committee for the Dorothy P. Landon-AACR Prize for Translational Cancer Research, AACR
- 2004-2007 Member, AACR Special Conferences Committee
- 2004-2012 Member, External Advisory Committee, Mayo Clinic Breast Cancer Program
- 2005-2006 Chair, ASCO Cancer Education Committee
- 2005-2006 Member, AACR Education Committee
- 2005-2008 Member, ASCO Translational Research Task Force
- 2006 Chair, Search Committee for Editor in Chief Oncology MKSAP
- 2007, 2008 Member, AACR-WICR Brigid G. Leventhal Scholar in Cancer Research Awards Committee
- 2006-2007 Member, ASCO Scientific Program Committee
- 2007-present Member, ASCO Advancing Research in Cancer Task Force
- 2007-2012 Member Steering Committee, AACR Cancer Immunology Working Group
- 2007-2010 Member, AACR Science Policy and Legislative Affairs Committee
- 2007-2009 Faculty Member and Member, Program Committee, Annual ASCO/AACR Clinical Trials Workshop
- 2008-2009 Co Chair, Program Committee, 2009 AACR Annual Meeting
- 2008-2010 Member, NIH Oversight Committee, National Clinical and Translational Science Award (CTSA) Consortium
- 2008-2010 Member, Scientific Review Committee, CTSC-AACR San Antonio Breast Cancer Symposium
- 2008-2009 Member, AACR Education Committee
- 2008, 2009 Working group member, Rapid Access to Preventive Intervention Development Program, Division of Cancer Prevention, NCI

- 2009 Chairperson, AACR 2009 Clinical and Translational Cancer Research Grants Committee
- 2009-2011 Course Director, ASCO/AACR Clinical Trials Workshop
- 2010, 2015-17 Chair, Grant Writing Workshop, ASCO Annual Meeting, Chicago, IL
- 2010 Scientific Review Committee, 9th Annual AACR International Conference on Frontiers in Cancer Prevention Research
- 2010-2011 Member, National Advisory Research Resources Council, National Institutes of Health
- 2011-2016 Member, External Advisory Board, University of Pittsburgh Cancer Center
- 2011-2016 Member, External Advisory Board, Karmanos Cancer Institute
- 2011 Member, Program Committee, AACR Annual Meeting
- 2011-present Member, External Steering Panel, Division of Cancer Prevention, NCI
- 2011-present Member, AACR Cancer Prevention Committee
- 2012-present Member, External Advisory Board, USC CTSA Program
- 2012-2016 Member, NIH Center for Advancing Translational Science (NCATS) Advisory Council
- 2012-2015 Member, NIH Cure Acceleration Network (CAN) Advisory Board
- 2013 Member, Abstract review committee, AACR Special Conference, Advances in Breast Cancer Research
- 2013-2015 Vice Chair, CTSA Steering Committee, NCATS
- 2013 Member, SITC Fellowship Award Review Committee
- 2013-2016 Member, Abstract Review Committee, San Antonio Breast Cancer Conference
- 2014-2015 Member, Steering Committee, SITC Immune Biomarkers Task Force
- 2015-2016 Member, Scientific Program Committee, AACR Annual Meeting, 2016
- 2016 Co-Chair, Immune Biomarkers Workshop, SITC-NCI, Bethesda, MD
- 2016-2017 Member, Scientific Program Committee, AACR Annual Meeting
- 2016-present Member, NCI Breast Cancer Steering Committee, Immuno-oncology Working Group
- 2017 Member, ASCO Educational Book, Expert Panel
- 2017 Organizer and Chair, ASCO-SITC Immuno-oncology Conference, Orlando, FL
- 2017 Faculty Member, ASCO University

National and International Study Section Duties

- 1996-1998 Member, Study Section, State of California Breast Cancer Research Program

1998-present Ad-hoc Reviewer, P01 Program, National Cancer Institute

1997-2000 Study Section, American Federation for Aging Research National Scientific Advisory Council

1997-1999 Study Section, Susan G. Komen Breast Cancer Foundation, National Scientific Advisory Council

1999 Study Section, RAID grants for the development of innovative technology, NIH/NCI

1999 Study Section, R03, Therapeutic Clinical Trials for Malignancies, NIH/NCI

2000 Study Section, Insight Awards to Stamp Out Breast Cancer, NIH/NCI

2001-2006 Member, Study Section, Clinical Oncology (CONC), NIH/NCI

2001 Ad hoc Reviewer, Subcommittee G-Education; NIH/NCI

2000-present Ad hoc Reviewer, CII Study Section, NIH/NCI

2002 Study Section, SPORE (Lymphoma), NIH/NCI

2002-2004 Chair, Innovative Treatment Study Section, State of California Breast Cancer Research Program

2002 Chair, Cell Biology and Immunology Study Section, DOD Ovarian Cancer Research Program

2002-2005 Member, Review Committee, Susan G. Komen Breast Cancer Foundation Postdoctoral Fellowship Awards

2003 Member, Translation Acceleration Site Visit Team, Canadian Breast Cancer Research Initiative, Canadian Institute of Cancer Research

2004 Study Section, SPORE (Head and Neck Cancer), NIH/NCI

2004-2007 Member, National Advisory Committee, Canadian Breast Cancer Research Initiative, Canadian Institute of Cancer Research

2006 Study Section, Department of Defense Ovarian Cancer Research Program

2007-present Member, Medical Scientific Review Committee, Ovarian Cancer Action, Helene Harris Memorial Trust

2007 Reviewer, NIH New Innovator Award

2008 Special Emphasis Panel Reviewer, NCI

2009 Member, Distinguished Editorial Panel, NCI, Director's Challenge Awards

2013 Chair, Cancer Biology/Immunology Study Section, Komen

2014 Reviewer, Komen Clinical Research Fellowships

2015-2017 Chair, SITC Fellowship Award Review Committee

2014-2015 Chair, Career Catalyst Awards Study Section, Komen Foundation

- 2016 Study Section Member, Career Catalyst Awards Study Section, Komen Foundation
- 2016 Chair, Fellowship Grant Program, SITC

Special Local Responsibilities:

- 1995-1997 Chair, Clinical Breast Cancer Working Group, FHCRC
- 1997-2005 Member, Executive Committee, Breast Cancer Program, FHCRC
- 1999-2013 Member, Executive Committee, SPORE in Ovarian Cancer, FHCRC
- 1999-2004 Chair, Scientific Program Committee, Pacific Ovarian Cancer Research Consortium
- 1999-2004 Member, General Clinical Research Center Scientific Advisory Committee, UW
- 1999-2013 Co-PI, SPORE in Ovarian Cancer, FHCRC
- 2000-present Co-Chair, Marsha Rivkin Ovarian Cancer Research Symposium
- 2000-2003 Co-Director, Translational Research, UW Breast Cancer Program
- 2001-2013 Associate Program Head, Gynecologic Oncology Program, FHCRC
- 2002-2004 Seattle Cancer Care Alliance Oncology Services Task Force, Co-leader Breast Cancer Subcommittee
- 2003-2005 Member, Consortium Scientific Steering Committee
- 2004-2008 Member, Oversight Committee for the Clinical Research Curriculum Award K30
- 2004-2008 Director, Division of Translational Research, K-12 Program (Multidisciplinary Clinical Research Career Development Program)
- 2006-present Research Advisory Board, Office of Research, UW
- 2007-present Member, Group Health Research Advisory Board
- 2009-present Member, Cancer Consortium Institutional Planning Committee
- 2009-present Member, University of Washington Stem Cell Institute
- 2009-present Member, Institutional Clinical Data Biorepository Committee
- 2009-2010 Member, Search Committee, Dean, School of Public Health, UW
- 2009 Toyota Lean Leadership Training Graduate
- 2011-present Member, University of Washington Center for AIDS Research
- 2013-2014 Member, Research Compliance and Integrity Committee
- 2015-present IAB Member, UW Diabetes Research Center
- 2015-present IAB Member, UW Institute for Protein Design
- 2015-present IAB Member, UW Stem Cell Institute

Research Funding:

A. Active Support

UL1TR000423/UL1 RR025014 (Disis) 09/17/2007 – 05/31/2017

NIH/(NCRR)/NCATS \$7,683,816

Institute for Translational Health Science (UL1)

The Institute of Translational Health Sciences is a partnership between the University of Washington, Fred Hutchinson Cancer Research Center, Children's Hospital and Regional Medical Center, and local and regional research and community partners. The ITHS functions as a "collaboratory"; a structure that spans all institutions to foster collaboration, career development, education, innovative technologies and resources, and the translational research process itself.

U01 CA154967 (Cheever) 09/22/2010 – 08/31/2016

NIH \$555,486 (Disis)

Cancer Immunotherapy Trials Network Central Operations and Statistical Center (CITN)

The goal of this project is to run a immunologic monitoring laboratory for the Cancer Immunotherapy Trials Network (CITN), a multi-institutional consortium, focused on early-phase clinical trials. Role: Co-Investigator

W81XWH-11-1-0760 (Disis) 09/30/2011 – 10/29/2016

DOD Transformative Vision Award \$1,389,213

Vaccine to Prevent Breast Cancer

This project aims to develop a multiantigen polyepitope Th vaccine targeting stem cell/EMT antigens for the prevention of breast cancer.

SAC130058 (Disis) 01/16/2014 – 01/15/2016

Susan G. Komen Foundation \$320,000

Limiting the inflammation of obesity to prevent breast cancer

The aims of this research are to (1) Identify immunogenic proteins associated with hypoxic pathways and metabolic dysregulation in obese adipocytes, (2) determine epitopes derived from the identified antigens that will preferentially elicit a Th2 CD4+ T cell response, and (3) evaluate whether an anti-inflammatory polyantigen vaccine will prevent the development of inflammatory obesity as well as breast cancer in obese mice.

OC130304 (Liao) 09/2/2014 – 09/01/2019

DoD \$81,152

Ovarian Cancer Research Program, Ovarian Cancer Academy Award – Early Career Investigators

Immune Profiling of BRCA1 and Platinum Resistance in Ovarian Cancer

The goals of this project are to develop and sustain of a successful independent career at the forefront of ovarian cancer research. Role: Mentor

Task Order: HHSN26100009 (Rao) 09/18/2014 – 09/17/2016

NIH/NCI Contract HHSN261201200013I \$487,073

Multi-antigen Vaccine for Lung Cancer Prevention

This project aims to identify and validate antigens that would be suitable for a vaccine to prevent some forms of non-small cell lung cancer by identifying up-regulated genes in bronchial dysplasia/CIS that are maintained during progression to invasive cancer.

Role: Co-Investigator

P50 CA083636 (Urban) 09/1/2009 – 06/30/2017

NIH/NCI \$46,641 (Disis)

Pacific Ovarian Cancer Research Consortium: SPORE Project 5: Vaccinating against IGFBP-2 to prevent ovarian cancer relapse

The goals of this project are to evaluate the immunogenicity, therapeutic efficacy, and safety of an IGFBP-2 polypeptide plasmid DNA vaccine in a mouse model, and conduct a Phase I clinical trial of active immunization with an IGFBP-2 DNA vaccine in patients with advanced stage ovarian cancer in the adjuvant setting. Role: Co-Investigator

5233194 (Disis) 06/15/2015 – 06/15/2016

Celgene Corporation \$184,893

Immunomodulators for Cancer Therapy

This contract supports the infrastructure for Celgene scientists to study the immune modulatory functions of a variety of agents that the company may want to take to clinic.

CRP-15-106-01-LIB (Disis) 07/01/2015 – 06/30/2020

American Cancer Society \$80,000

Vaccines Targeting Cancer Initiation Antigens to Prevent Colon Cancer

This project proposes to develop a multi-antigen vaccine for colon cancer prevention composed of sequences derived from "initiation antigens" that only stimulate Th1 immunity. We will test the safety of immunization and whether the vaccine is effective in preventing either adenomas or invasive cancers in mouse models. These data will lay the foundation for a first-in-man study of the approach.

HHSN261201200033I (Bailey) 07/01/2015 – 06/30/2019

NCI \$669,241

A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine (WOKVAC) Encoding Epitopes Derived from Three Breast Cancer Antigens (IGFBP-2, HER2, and IGF-IR) in Patients with Breast Cancer

This proposal aims to assess the safety of a DNA plasmid based vaccine encoding three breast cancer antigens (IGFBP2, HER2, and IGF-IR) in patients with breast cancer at 3 escalating doses.

Role: Protocol PI

BCRF-16-038 (Disis) 10/01/2016 – 09/30/2017

Breast Cancer Research Foundation \$208,333

Adoptive T-cell therapy with HER2 specific polyfunctional Th1/17 cells in HER2+metastatic breast cancer

This proposal will determine the extent to which neu specific polyfunctional Th1/17 cells induce epitope spreading and persist in vivo after adoptive transfer and will determine the reproducibility of expansion of human HER2 specific Th1/17 cells for clinical use. The resulting data will support an investigation new drug application (IND) for HER2 specific Th1/17 cell infusions for the treatment of metastatic HER2+ breast cancer.

B. Examples of Projects Completed:

- R01 CA129517, Adoptive T Cell Therapy for the Treatment of HER2 Overexpressing Cancers, NIH, 2008-2013, Funding \$399,810/yr (PI: Disis)
- R01 AT004314, Mechanisms of Immunomodulatory and Anti-Tumor Actions of Polysaccharide Krestin, NCI, 2007-2011, Funding: \$250,000/yr (P.I. Disis)
- R01 CA098761, Phase I Clinical Trial of a HER2 ICD Plasmid Based DNA Vaccine in Patients with HER2 Overexpressing Breast and Ovarian Cancer, 2003-2009, Funding \$904,715/yr (PI Disis)
- M01 RR00037, General Clinical Research Center, NCRR, 2004-2007, Funding \$5,857,106/yr (PI Ramsey)
- R01 CA85374, HER2 Specific T Cell Infusions Following HER2 Peptide Based Vaccination for the Treatment of HER2 Overexpressing Malignancy, NCI, 2000-2006, Funding, \$335,000/yr (PI Disis)
- U54 CA090818, Immunologic Correlates of Effective Immunization for Cancer Vaccines, NCI, 2001-2006, Funding, \$1,300,000/yr (PI Disis)
- K24 CA85218, *Midcareer Investigator Award in Patient Oriented Research*, NCI, 2000-2005, Funding: \$107,888/yr (P.I. Disis)
- R01 CA75163, *HER2 Peptide Vaccines in Patients with HER2 Expressing Cancers*, NCI, 1997-2001, Funding: \$107,547/yr (P.I. Disis)

Bibliography

A. Peer-Reviewed Publications of Original Work:

1. Disis, M.L., McDonald, T.L., Colombo, J.L., Kobayashi, R.H., Angle, C.R., and Murray, S.: Circulating immune complexes in cystic fibrosis and their correlation to clinical parameters. *Pediatric Research*. 20: 385-390, 1986.
2. Peace, D.J., Smith J.W., Disis, M.L., Chen, W. and Cheever, M.A.: Induction of T cells specific for the mutated segment of oncogenic p21^{ras} protein by immunization in vivo with the oncogenic protein. *J. Immunotherapy*. 14: 110-114, 1993.
3. Cheever, M.A., Chen, W., Disis, M.L., Takahashi, M., Peace, D.J.: T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl. *Ann NY Acad Sci*. 690:101-12, 1993.
4. Disis, M.L., Calenoff, E., Murphy, A.E., Chen, W., Groner, B., Jescke, M., Lydon, N., McGlynn, E., Livingston, R.B., Moe, R, and Cheever, M.A.: Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. *Cancer Research*. 54: 16-20, 1994.
5. Disis, M.L., Smith, J.W., Murphy, A.E., Chen, W., and Cheever, M.A.: In vitro generation of human cytolytic T cells specific for peptides derived from HER-2/neu proto-oncogene protein. *Cancer Research*. 54: 1071-1076, 1994.
6. Bernhard, H., Disis, M.L., Heimfeld, S., Hand, S., Gralow, J.R., and Cheever, M.A.: Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic

- progenitor cells of the bone marrow and peripheral blood. Cancer Research. 55:1099-1104, 1995.
7. Qin, H., Chen, W., Takahashi, M., Disis, M.L., Byrd, D.R., McCahill, L., Bertram, K.A., Fenton, R.G., Peace, D.J., and Cheever, M.A.: CD4+ T cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Research. 55: 2984-2987, 1995.
 8. Takahashi, M., Chen, W., Byrd, D.R., Disis, M.L., Huseby, E., McCahill, L., Nelson, H., Peace, D.J., Qin, H.L., Shimada, H., Okuno, K., Yasutomi, M., and Cheever, M.A.: Antibody responses to ras proteins in patients with colon cancer. Clin. Cancer Research. 1 (10): 1071-1077, 1995.
 9. Disis, M.L., Gralow, J.R., Bernhard, H., Hand, S.L., Rubin, W.D., and Cheever, M.A.: Peptide based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self protein. J. Immunology. 156: 3151-3158, 1996.
 10. Disis, M.L., Bernhard, H., Shiota, F.M., Hand, S.L., Gralow J.R., and Cheever, M.A.: GM-CSF: An effective adjuvant for protein and peptide based vaccines. Blood. 88 (1): 202-210, 1996.
 11. Lustgarten, J., Theobald, M., Labadie, C., LaFace, D., Peterson, P., Disis, M.L., Cheever, M.A., and Sherman, L.A.: Identification of HER-2/neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8. Human Immunology. 52(2): 109-118, 1997.
 12. Disis, M.L., Pupa, S.M., Gralow, J.R., Dittadi, R., Menard, S., and Cheever, M.A.: High titer HER-2/neu protein specific antibody immunity can be detected in patients with breast cancer. J. Clinical Oncology. 15 (11): 3363-3367, 1997.
 13. Disis, M.L., Shiota, F.M., and Cheever, M.A.: Human HER-2/neu protein immunization circumvents tolerance to rat neu: A vaccine strategy for "self" tumor antigens. Immunology. 93: 192-199, 1998.
 14. McNeel, D.G., Schiffman, K.A., and Disis, M.L.: Immunization with rhGM-CSF as a vaccine adjuvant elicits both a cellular and humoral response to rhGM-CSF. Blood. 93: 2653-2659, 1999.
 15. Ward, R.L., Hawkins, N.J., Coomber, D., and Disis, M.L.: Antibody immunity to the HER-2/neu protein in patients with colon cancer. Human Immunology. 60:510-515, 1999.
 16. Rinn, K., Schiffman, K., Otero, H.O., and Disis, M.L.: Antigen-specific recall urticaria to a tumor vaccine. J. All. Clin. Immunol. 104 :240-242, 1999.
 17. Disis, M.L., Grabstein, K. H., Sleath, P. R., and Cheever, M.A.: Generation of immunity to the HER-2/neu oncogenic protein in breast and ovarian cancer patients using a peptide based vaccine. Clin. Cancer Research. 5:1289-1297, 1999.
 18. Bernhard, H. Huseby, E.S., Hand, S.L., Lohmann, M., Batten, W.Y., Disis, M.L., Gralow, J.R., Meyer zum Bruschenfelde, K-H, Ohlen, C., and Cheever, M.A.: Dendritic cells lose ability to present protein antigen after stimulating antigen-specific T cell responses despite upregulation of MHC Class II expression. Immunobiology. 201: 568-582, 2000.
 19. Disis, M.L., Schiffman, K., Gooley, T.A., McNeel, D.G., Rinn, K., and Knutson, K.L.: Delayed type hypersensitivity response (DTH) is a predictor of peripheral blood T cell immunity after HER-2/neu peptide immunization. Clin. Cancer Research. 6(4):1347-50, 2000.
 20. Schiffman, K. and Disis, M.L.: HER-2/neu peptide based vaccines, with GM-CSF as an adjuvant, in patients with advanced stage HER2/neu expressing cancers. Clin. Lung Cancer. 2(1): 74-77, 2000.
 21. Gaiger, A., Reese, V., Disis, M.L. and Cheever, M.A.: Immunity to WT-1 in the animal model and in patients with acute myeloid leukemia. Blood. 96 (4):1480-1489, 2000.
 22. McNeel, D.G., Nguyen, L.D., Storer, B., Vessella, R., Lange, P.H. and Disis, M.L.: Antibody immunity to prostate cancer-associated antigens can be detected in the serum of patients with prostate cancer. J. of Urology. 164:1825-1829, 2000.

23. Disis, M.L., Knutson, K.L., Schiffman, K., Rinn, K., and McNeel, D.G.: Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Research and Treatment. 62(3):245-52, 2000.
24. Knutson, K.L. and Disis, M.L.: Expansion of HER-2/neu specific T cells ex vivo following immunization with a HER-2/neu peptide based vaccine., Clin. Breast Cancer. 2:73-79, 2001.
25. Knutson, K.L., Schiffman, K., and Disis, M.L.: Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T cell immunity in cancer patients. J. Clin. Investigation. 107:477-484, 2001.
26. McNeel, D.G., Nguyen, L.D., Ellis, W.J., Higano, C.S., Lange, P.H., and Disis, M.L.: Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. Prostate, 47: 222-229, 2001.
27. McNeel, D.G., Nguyen, L.D., and Disis, M.L.: Identification of T helper epitopes derived from prostatic acid phosphatase. Cancer Research, 61(13):5161-7, 2001.
28. Knutson, K.L and Disis, M.L.: Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine. Clin Breast Cancer. 2(1): 73-9, 2001.
29. Disis, M.L., Gooley, T.A., Rinn, K., Davis, D., Peipkorn, M., Cheever, M.A., Knutson, K.L., and Schiffman, K.: Generation of T cell immunity to the HER-2/neu protein after active immunization with a HER-2/neu peptide based vaccine. J. Clinical Oncology, 20(11): 2624-2632, 2002.
30. Schiffman, K., Rinn, K., and Disis, M.L.: Delayed type hypersensitivity (DTH) response to recall antigens does not accurately reflect immune competence in advanced stage cancer patients. Breast Cancer Research and Treatment, 74(1):17-23., 2002.
31. Disis, M.L., Rinn, K., Knutson, K.L., Davis, D., Caron, D., dela Rosa, C., and Schiffman, K: Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide based vaccines in patients with HER-2/neu overexpressing cancers. Blood, 99(8):2845-2850, 2002.
32. Knutson, K.L., Schiffman, K. Cheever, M.A., and Disis, M.L.: Immunization of cancer patients with a HER-2/neu HLA-A2 peptide, p369-377, results in short-lived peptide specific immunity. Clin. Cancer Research, 8 (5): 1014-1018, 2002.
33. Knutson, K.L. and Disis, M.L.: Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient. Human Immunology, 63 (7): 547-557, 2002.
34. Ginsburg, A.S., Salazar, L.G., True, L.D., and Disis. M.L.: Fatal Bacillus cereus sepsis following resolving neutropenic enterocolitis during the treatment of acute leukemia. American Journal of Hematology, Mar;72 (3):204-8, 2003.
35. McNeel, D.G., Knutson, K.L., Schiffman, K., Davis, D., Caron, D., and Disis, M.L.: Pilot study of an HLA-A2 peptide-based vaccine using Flt3 ligand as a systemic vaccine adjuvant. J Clin. Immunology, 23 (1);62-72, 2003.
36. Disis, M.L., Shiota, F.M., McNeel, D.G., and Knutson, K.L.: Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self-tumor antigens. Immunobiology, 207: 179-186, 2003.
37. Dols, A., Meijer, S.L., Hu, H.M., Goodell, V., Disis, M.L., von Mensdorff-Pouilly, S., Verheijen, R., Alvord, W.G., Smith, J., Urba, W.J., and Fox, B.A.: Identification of tumor specific antibodies in patients with breast cancer vaccinated with gene modified allogeneic tumor cells. J. Immunotherapy, Mar-Apr; 26 (2):163-170, 2003.
38. Salazar LG, Fikes, J., Southwood, S., Ishioka, G., Knutson KL, Gooley, T.A., Schiffman K, and Disis ML: Immunization of cancer patients with HER-2/neu derived peptides demonstrating high affinity binding to multiple class II alleles. Clin Cancer Research, Nov. 15; 9 (15): 5559-5565, 2003.

39. Disis, M.L., Scholler, N., Dahlin, A., Pullman, J., Knutson, K.L., Hellstrom, K.E., and Hellstrom, I.: Plasmid based vaccines encoding rat neu and co-stimulatory molecules elicit neu specific immunity. Molecular Cancer Therapeutics, 2: 995-1002, 2003.
40. Knutson, K.L. and Disis, M.L.: IL-12 enhances the generation of tumor antigen specific Th1 CD4+ T cells during ex vivo expansion. Clin. Exp. Immunol, Feb;135 (2): 322-329, 2004.
41. Knutson, K.L., Almand, B., Dang, Y., and Disis, M.L.: Neu antigen negative variants can be generated following neu-specific antibody therapy in neu-transgenic mice. Cancer Research, Feb 1;64 (3): 1146-1151, 2004.
42. Disis, M.L., Goodell, V., Schiffman, K, and Knutson, K.L.: Humoral epitope spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J. Clinical Immunology, 24 (5):571-8, 2004.
43. Curiel T.J., Coukos, G., Zou, L., Xavier, A., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J.R., Zhang, L., Burow, M., Zhu, Y., Wei, S., Kryczek, I., Daniel, B., Gordon, A., Myers, L., Lackner, A., Disis, K.L., Knutson, K.L., Chen, L., and Zou, W.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine, 10:942-949, 2004.
44. Disis M.L., Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, dela Rosa C, and Cheever MA: Effect of dose on immune response in patients vaccinated with a HER-2/neu intracellular domain protein based vaccine., J Clinical Oncology, May 15;22 (10):1916-1925, 2004.
45. Montgomery, R.B., Makary, E., Schiffman, K., Goodell, V., and Disis, M.L.: Endogenous anti-HER2 antibodies suppress HER2 phosphorylation and signaling through extracellular signal-regulated kinase., Cancer Research, Jan 15;65(2):650-656, 2005.
46. Goodell, V. and Disis, M.L.: Human tumor cell lysates as a protein source for the detection of cancer antigen specific humoral immunity. Journal of Immunologic Methods, April 299:1-2:129-138, 2005.
47. Maecker, H.T., Moon, J., Bhatia, S., Ghanekar, S.A., Maino, V.C., Payne, J.K., Kuus-Reichel, K., Chang, J., Summers, A., Clay, T.M., Morse, M.A., Lyster, H.K., delaRosa, C., Ankerst, D.P., and Disis, M.L.: Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT assays. BMC Immunology, Jul 18; 6(1):17, 2005.
48. Yang J., Huston L., Berger D., Danke N.A., Liu A,W., Disis M.L., and W.W. Kwok: Expression of HLA-DP0401 molecules for identification of DP0401 restricted antigen specific T cells. J Clinical Immunology, Sep;25(5):428-36, 2005.
49. Wallden, B., Edmond, M., Swift, M.E., Disis, M.L. and Swisshelm, K.: Antimetastatic gene expression profiles mediated by retinoic acid beta 2 in MDA-MB-435 breast cancer cells. BMC Cancer, 5:140, 2005.
50. Manjili, MH, Arnouk, H, Knutson, KL, Kmiecik, M, Disis, ML, Subjeck, JR, and Kazim, AL: Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce danger signals", Breast Cancer Res Treat, 96(3):243, 2006.
51. Disis, M.L., delaRosa, C., Goodell, V., Kuan, L-Y, Chang, J.C.C., Kuus-Reichel, K., Clay, T., Lyster, H.K., Waters, C. A., Ghanekar, S.A., Maino, V.C., and Maecker, H.T.: Maximizing the retention of antigen specific lymphocyte function after cryopreservation, Journal of Immunologic Methods, Jan 20; 308(1-2):13-18, 2006.
52. Goodell, V, Salazar, L. G. Urban, N., Drescher, C., Gray, H., Swensen, R., McIntosh, M.W., and Disis, M.L.: Antibody immunity to the p53 oncogenic proteins is a prognostic indicator in ovarian cancer. J. Clinical Oncology, Feb 10; 24:762-768, 2006.
53. Thompson, J.A., Dissanayake, S.K., Ksander, B.R., Knutson, K.L., Disis, M.L., and Ostrand-Rosenberg, S.: Tumor cells transduced with the MHC Class II transactivator and CD80 activate tumor specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Research, Jan 15; 66(2):1147-1154, 2006.

54. Zhang, H., Knutson, K.L., Hellstrom, K.E., Disis, M.L., and Hellstrom, I.: Anti-tumor efficacy of CD137 ligation is maximized by the use of a CD137 scFv expressing whole cell tumor vaccine as compared to CD137 specific monoclonal antibody infusion. Molecular Cancer Therapeutics, Jan;5 (1):149-155, 2006.
55. Knutson, K.L., Dang, Y., Lu, H., Lukas, J., Almand, B., Makary, E., Azeke, E., and Disis, M.L.: IL-2 immunotoxin therapy modulates tumor associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunology, Jul 1; 177(1):84-91, 2006.
56. Knutson, K.L., Lu, H., Stone, B., Reiman, J.M, Behrens, M.D., Prosperi, C.M., Gad, E., Smorlesi, A., and Disis, M.L.: Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunology, Aug 1:177(3):1526-33, 2006.
57. Benz, C.C., Fedele, V., Xu, F., Ylstra, B., Ginzinger, D., Yu, M., Moore, D., Kneuper Hall, R.K., Wolff, D.J., Disis, M.L., Eppenberger-Castori, S., Eppenberger, U., Schittuli, F., Tommasi, S., Paradiso, A., Scott, G.K., and Albertson, D.G.: Altered promoter usage characterizes monoallelic transcription arising with ERB2 amplification in human breast cancers. Genes, Chromosomes and Cancer, Nov;45(11):983-984, 2006.
58. Lu, H., Knutson, K.L., Gad, E., and Disis, M.L.: The tumor antigen repertoire identified in tumor bearing neu transgenic mice predicts human tumor antigens. Cancer Research, Oct. 1; 66(19):9754-61, 2006.
59. Wang, L.X, Shu, S., Disis, M.L. and Plautz, G.E.: Adoptive transfer of tumor-primed in vitro activated CD4+ T-effectors combined with CD8+ T effectors provides intratumoral T cell proliferation and synergistic anti-tumor response. Blood, Jun 1;109(11):4865-4876, 2007.
60. Dang, Y., Knutson, K.L., Goodell, V., delaRosa, C., Salazar, L.G., Higgins, D., Childs, J., and Disis, M.L.: Tumor antigen specific T cell expansion is greatly facilitated by in vivo priming. Clin Cancer Research, Mar 15; 13(6):1883-1891, 2007.
61. Goodell, V., dela Rosa, C., Slota, M., MacLeod, B, and Disis, M.L. Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses. BMC Immunology, Sep 12;8:21, 2007.
62. Ghanekar, SA, Bhatia, S, Ruitenber, JJ, delaRosa, C, Disis, ML, Maino, VC, Maeker, HT, and Waters, CA: Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors. Journal of Immune Based Therapies and Vaccines; 5:7, 2007.
63. Inokuma, M., delaRosa, C., Schmitt, C., Haaland, P., Siebert, J., Petry, D., Tang, M.X., Suni, M.A., Ghanekar, S.A., Gladding, D., Dunne, J.F., Maino, V.C., Disis, M.L., and Maecker, H.T.: Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature, J. Immunology, 179:2627-2633, 2007.
64. Salazar, L.G., Coveler, A.L., Swensen, R.E., Gooley, T.A., Goodell, V., Schiffman, K., and Disis, M.L. Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers. Clinical Immunology, Dec; 125(3):275-280, 2007.
65. Goodell, V., Waisman, J., Salazar, L.G., dela Rosa, C., Link, J., Coveler, A.L., Webster, W., Childs, J. S., Fintak, P.A., Higgins, D.M., and Disis, M.L. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Molecular Cancer Therapeutics, 7(3):449-54, 2008.
66. Siebert, J.C., Inokuma, M., Waid, D.M., Pennock, N.D., Vaitaitis, G.M., Disis, M.L., Dunne, J.F., Wagner, D.H., and Maecker, H.T.: An analytical workflow for investigating cytokine profiles. Cytometry A, 73(4):289-98, 2008.
67. Behrens, M.D., Wagner, W.M., Krco, C.J., Erskine, C.L., Kalli, K.R., Krempski, J., Gad, E.A., Disis, M.L., and Knutson, K.L.: The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood, 111(3):1472-9, 2008.

68. Coveler, A. L., Goodell, V., Webster, D.J., Salazar, L.G., Fintak, P.A., Childs, J.S., Higgins, D.M., and Disis, M.L.: Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced immunity. Breast Cancer Research Treatment, 113(1):95-100, 2009. Epub 2008 Jan 31.
69. Maecker, H.T., Hassler, J., Payne, J.K., Summers, A., Comatas, K., Ghanayem, M., Morse, M.A., Clay, T.M., Lyster, H.K., Bhatia, S., Ghanekar, S.A., Maino, V.C., delaRosa, C., and Disis, M.L.: Precision and linearity targets for validation of an IFN γ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunology, 9:9, 2008.
70. Goodell, V., McNeel, D., Disis, M.L.: His-tag ELISA for the detection of humoral tumor-specific immunity. BMC Immunology, 9:23, 2008
71. Kalli, K.R., Krco, C.J., Hartmann, L.C., Goodman, K., Maurer J., Yu, C., Johnson, E.M., Erksine, C.L., Disis, M.L., Wettstein, P.J., Fikes, J.D., Beebe, M., Ishioka, G., and Knutson, K.L.: An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. Cancer Research, Jun 15; 68(12): 4893-901, 2008.
72. Lu, H, Goodell, V., and Disis, M.L.; Humoral immunity directed against tumor associated antigens as potential biomarkers for the early diagnosis of cancer. J of Proteome Research, Apr; 7(4): 1388-94, 2008.
73. Park, K.H., Gad, E., Goodell, V., Dang, Y., Wild, T., Higgins, D. Fintak, P., Childs, J., delaRosa, C, and Disis, M.L.: Insulin like growth factor binding protein 2 is a target for the immunomodulation of breast cancer. Cancer Research, 68 (20):1-10, 2008.
74. Ladd, J., Lu, H., Taylor, A.D., Goodell, V., Disis, M.L. and Jiang, S. Direct detection of carcinoembryonic antigen autoantibodies in clinical serum samples using a surface Plasmon resonance sensor. Colloids and Surfaces B: Biointerfaces. (epub ahead of print), 2009.
75. Disis, M.L., Wallace, D. Gooley, T.A., Dang, Y., Slota, M., Lu, H., Coveler, A., Childs, J., Higgins, D., Fintak, P., delaRosa, C., Tietje, K., Link, J., Waisman, J., and Salazar, L.G.: Concurrent trastuzumab and HER-2/neu specific vaccination in patients with metastatic breast cancer. J Clinical Oncology, Oct 1;27(28):4685-4692, 2009.
76. Li Z, Liu Y, Tuve S, Xun Y, Fan X, Min L, Feng Q, Kiviat N, Kiem HP, Disis ML, and Lieber A.: Towards a stem cell gene therapy for breast cancer, Blood, May 28; 113(22):5423-33, 2009.
77. Tuve S., Liu Y., Traqoolpua K., Jacobs JD, Yumul RC, Li ZY, Strauss R, Hellstrom KE, Disis ML, Roffler S, and Lieber A. In situ adenovirus vaccination engages T effector cells against cancer, Vaccine, June 24;27(31): 4225-4239, 2009.
78. Emens L., Asquith J., Leatherman J., Kobrin B., Petrik S., Laiko M., Levi J., Daphtary M., Biedrzycki B., Wolff A., Stearns V., Disis M., Ye X., Piantadosi S., Fetting J., Davidson N., and Jaffee E.: Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation, J Clinical Oncology, 27 (35):5911-5918, 2009.
79. Karyampudi L, Krco CJ, Kalli KR, Erskine CL, Hartmann LC, Goodman K, Ingle JN, Maurer MJ, Nassar A, Yu C, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, and Knutson KL: Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. Cancer Immunol Immunother, 59 (1): 161-171, 2010.
80. Karyampudi., L, Formicola, C., Erskine, C.L., Maurer, M.J., Ingle, J.N., Krco, C.J., Wettstein, P.J., Kalli, K R., Fikes, J.D, Beebe, M., Hartmann, L.C., Disis, M.L., Ferrone, S., Ishioka, G., and Knutson, K.L.: A degenerate HLA-DR epitope pool of HER-2/neu antigen reveals a novel *in vivo* immunodominant epitope, HER-2/neu88-102. Clin Cancer Research, 16 (3):825-34, 2010.

81. Olson, BM, Frye TP, Johnson LE, Fong L, Knutson, KL, Disis, ML and McNeel, DG: HLA-A2 restricted T cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother, 59;(6), 943-953, 2010.
82. Lu, H, Wagner, WM, Gad, E, Yang, Y, Duan, H, Amon, LM, Van Denend, N, Larson, ER, Chang, A, Tufvesson, H, and Disis, ML: Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade, J Immunology, 184 (9):5360-5367, 2010.
83. Kievit, FM, Florczyk, SJ, Leung, M, Veiseh, O, Park, JO, Disis, ML, and Zhang, M: Chitosan-alginate 3D scaffolds as a mimic of the glioma tumor microenvironment. Biomaterials, Aug; 31(22):5903-10, 2010.
84. Paulson,KG, Iyer, JG, Tegeder, AR, Thibodeau, R, Schelter, J, Koba, S, Schrama, D, Simonson, WT, Lemos, BD, Byrd, DR, Koelle, DM, Galloway,DA, Leonard, JH, Madeleine, MM, Argenyi, ZB, Disis, ML, Becker, JC, Cleary, MA, Nghiem, P: Transcriptome-wide studies of Merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clinical Oncology, 2011 Apr 20; 29(12):1539-46. Epub 2011 Mar 21. PMID: 21422430
85. Lu, H., Yang Y., Gad E., Wenner, CA., Chang A., Larson ER., Dang Y., Martzen M., Standish, LJ., and Disis, ML.: Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Research, 2011 Jan 1; 17(1):67-76. Epub 2010 Nov 10. PMID: 21068144
86. Lu, H., Yang, Y., Gad, E., Inatsuka, C., Wenner, C.A., Disis, M.L., and Standish, L.J.: TLR2 agonist PSK activates human NK cells and enhances the anti-tumor effect of HER2-targeted monoclonal antibody therapy, Clin Cancer Research, 2011 Nov 1;17(21):6742-53. Epub 2011 Sep 14. PMID: 21918170
87. Hahn, T., Bradley-Dunlop, D.J., Hurley, L.H., Von Hoff, D., Gately, S., Disis, M.L., Lu, H., Penichet, M.L., Besselsen, D.G., Cole, B.B., Meeuwsen, T., Walker, E., and Akporiaye, E.T.: The vitamin E analog, alpha-tocopheryloxyacetic acid, enhances the anti-tumor activity of trastuzumab against HER-2/neu expressing breast cancer. BMC Cancer, 2011 Nov 2; 11:471. PMID: 22044845
88. Lu, H., Dietsch, G.N., Matthwes, M.H., Yang, Y., Ghanekar, S., Inokuma, M., Suni, M., Maino, V.C., Henderson, K.E., Howbert, J.J., Disis, M.L., and Hershberg, R.M.: VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Research, 2012 Jan 15; 18(2):499-509. PMID: 22128302
89. Kievit, FM, Stephen, ZR, Veiseh, O, Arami, H, Wang, T, Lai, VP, Park, JO, Ellenbogen, RG, Disis, ML, and Zhang, M: Targeting of primary breast cancer and metastasis in a transgenic mouse model using rationally designed multifunctional SPIONs. ACS Nano, 2012 Mar 27; 6(3):2591-601. PMID: 22324543
90. Amon LM, Pitteri SJ, Li CI, McIntosh, M, Ladd JJ, Disis M, Porter P, Wong, CH, Zhang Q, Lampe P, Prentice RL, and Hanash SM: Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer. Cancer Research, 2012 Apr 15; 72(8):1935-42. PMID: 22367215
91. Dang Y., Wagner, WM, Gad, E., Rastetter, L., Berger, CM, Holt, GE, and Disis, ML.: Dendritic cell stimulating vaccine adjuvants differ in the ability to elicit anti-tumor immunity due to an adjuvant specific induction of immune suppressive cells. Clin Cancer Research, 2012 Jun 1; 18(11):3122-31. PMID: 22510348
92. Lu, H., Ladd, J., Feng, Z., Wu, M., Goodell, V., Pitteri, SJ., Li, C., Prentice, R., Hanash, SH., and Disis, ML: Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in pre-diagnostic breast cancer sera. Cancer Prevention Research, 2012 Aug; 5(8):1036-43. PMID: 22715141
93. Ladd, JJ, Chao T, Johnson, M, Qui JI, Chin, A, Israel, R, Pitteri, SJ, Mao, J, Wu, M, Amon, L, McIntosh, M., Li, C., Prentice, RL, Disis, ML, and Hanash, SM: Autoantibody signatures

- involving glycolysis and spliceosome proteins precede a diagnosis of breast cancer among postmenopausal women. Cancer Research. 2013 Mar 1; 73(5):1502-13. Epub 2012 Dec 26. PMID: 23269276
94. Phan-Lai, V., Florczyk, S.J., Kievit, F.M., Wang, K., Gad, E., Disis, M.L. and Zhang, M.: Three-dimensional scaffolds to evaluate tumor associated fibroblast-mediated suppression of breast tumor specific T-cells. Biomacromolecules. 2013 May 13; 14(5):1330-7. Epub 2013 Apr 3. PMID: 23517456
 95. Cecil, D.L., Park, K.H., Gad, E., Childs, J.S., Higgins, D.M., Plymate, S.R., and Disis, M.L.: T-helper I immunity, specific for the breast cancer antigen Insulin-like growth factor I receptor (IGF-IR), is associated with increased adiposity. Breast Cancer Research and Treatment, 2013 Jun; 139(3):657-65. Epub 2013 Jun 8. PMID: 23749321.
 96. Chao T, Ladd, J, Qui JI, Johnson, M M, Israel, R, Chin, A., Wang H., Prentice, RL, Feng, Z., Disis, ML, and Hanash, SM: Proteomic profiling of the autoimmune response to breast cancer antigens uncovers a suppressive effect of hormone therapy. Prot Clin Applications, 2013 Jun; 7(5-6):327-36. Epub 2013 May 10. PMID: 23401414
 97. Broussard, E.K., Kim, R., Wiley, J.C., Pritchard, D., Marquez, J.P., Annis, J.E., and Disis, M.L.: Identification of Putative Immunologic Targets for Colon Cancer Prevention Based on Conserved Gene Upregulation from Preinvasive to Malignant Lesions. Cancer Prevention Research, 2013 Jul; 6(7):666-74. Epub 2013 May 16. PMID: 23682078.
 98. Inatsuka, C., Yang, Y., Gad, E., Rastetter, L., Disis, M.L., and Lu, H.: Gamma delta T-cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK. Cancer Immunol Immunother., 2013 Aug; 62(8):1335-45. Epub 2013 May 18. PMID 23685781.
 99. Disis, M.L., Dang, Y., Coveler, A.L., Marzbani, E., Kou, Z.C., Childs, J.S., Fintak, P., Higgins, D.M., Reichow, J., Waisman, J. and Salazar, L.G.: HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers. Cancer Immunol Immunother., 2014 Feb; 63(2):101-9. Epub 2013 Oct 26. PMID: 24162107.
 100. Engel, A.L., Sun, G.C., Gad, E., Rastetter, L.R., Strobe, K., Yang, Y., Dang, Y., Disis, M.L., and Lu, H.: Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant. Immunobiology, 2013 Dec; 218(12):1468-76. Epub 2013 May 13. PMID: 23735481.
 101. Disis, M.L., Gad, E. Herendeen, D.R., Lai, V.P., Park, K.H., Cecil, D.L., O'Meara, M.M., Treuting, P.M., and Lubet, R.A.: A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. Cancer Prevention Research, 2013 Dec; 6(12):1273-82. PMID: 24154719
 102. Yang, Y., Inatsuka, C., Gad, E., Disis, M.L., Standish, L.J., Pugh, N., Pasco, D.S. and Lu, H: Protein-bound polysaccharide K induces IL-1B via TLR2 and NLRP3 inflammasome activation. Innate Immunity, 2013 Dec 9. PMID: 24323452
 103. Phan-Lai, V., Kievit, F.M., Florczyk, S.J., Wang, K., Disis, M.L., and Zhang, M.: CCL21 and IFN-g recruit and activate tumor specific T-cells in 3D scaffold model of breast cancer. Anti-Cancer Antigens Med Chem., 2014 Feb; 14(2):204-10. PMID 24237220
 104. Mao, J., Ladd, J., Gad, E., Rastetter, L., Johnson M.M., Marzbani, E., Childs, J.S., Lu, H., Dang, Y., Broussard, E.M., Stanton, S., Hanash, S. M., and Disis, M.L.: Mining the pre-diagnostic antibody repertoire of TgMMTV-neu mice to identify autoantibodies useful for the early detection of human breast cancer. Journal of Translational Medicine, 2014 May 10; 12:121. PMID: 24886063
 105. Cecil, D.L., Holt, G.E., Park, K.H., Gad, E., Rastetter, L., Childs, J., Higgins, D., and Disis, M.L. Elimination of IL-10 inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent anti-tumor activity. Cancer Research, 2014 May 15; 74(10):2710-8. PMID: 24778415

106. Gad, E, Rastetter, L.M., Slota, M., Koehnlein, M., Trueting, P.M., Dang Y., Stanton, S., and Mary L. Disis: Natural history of tumor growth, metastasis, and tumor immune infiltrates in common spontaneous murine mammary tumor models. Breast Cancer Res Treat, DOI 10.1007/s10549-014-3199-9, 2014. PMID: 25395320
107. Paulson, K.E., Tegeder, A., Willmes, C., Iyer, J.G., Afanasiev, O.K., Schrama, D., Koba, S., Thibodeau, R., Nagase, K., Simonson, W.T., Seo, A., Koelle, D.M., Madeleine, M., Bhatia, S., Nakajima, H., Sano, S., Hardwick, J.S., Disis, M.L., Cleary, M.A., Becker, J.C. and Nghiem, P.: Down regulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma. Cancer Immunology Research. Nov; 2(11):1071-9, 2014. PMID:25116754
108. Gil, E.Y., Jo, U.H., Lee, H.J., Kamg, J., Seo, J.H., Lee, E.S., Kim, Y.H., Kim, I., Lai, V.P., Disis, M.L., and Park, K.H. Vaccination with ErbB-2 peptides prevent cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice. Breast Cancer Res Treat, Aug; 147 (1); 69-80, 2014. PMID: 25104444
109. Ebben, J.D., Lubet, R.A., Gad, E., Disis, M.L. and You, M.: Prevention of EGFR driven lung adenocarcinoma in transgenic mice expressing mutant human EGFR by a multivalent EGFR peptide vaccine. Molecular Carcinogenesis, Sept. 7, doi: 10.1002/mc.22405. [Epub ahead of print], 2015. PMID: 26346412.
110. Katayama H., Boldt, C., Ladd, J.J., Johnson, M.M., Chao, T., Capello, M., Suo, J., Mao, J., Manson, J., Prentice, R., Esteva, F., Wang, H., Disis, M.L., and Hanash, S.: An autoimmune response signature associated with the development of triple negative breast cancer reflects disease pathogenesis. Cancer Research, Aug. 15; 75(16):3246-54, 2015. PMID: 26088128
111. Liao, JB, Ovenell, KS, Curtis, EM, Cecil, DL, Koehnlein, MR, Rastetter, LR, Gad, EA and Disis, ML: Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer. J Immunother of Ca. 3:16, 2015.
112. Phan-Lai, V, Dang, Y, Gad, E, Childs, J, and Disis, ML: The anti-tumor efficacy of IL-2/IL-21-cultured polyfunctional neu-specific T-cells is TNF-alpha/IL-17 dependent. Clinical Cancer Research, Dec. 9, (e-pub), 2015.
113. Dietsch, G.N., Lu, H., Yang, Yi., Morishima, C., Chow, L.Q., Disis, M.L., and Hershberg, R.M.: Coordinate activation of TLR8 and NLRP3 by VTX-2337 ignites tumoricidal NK cell activity. Plos One, Feb. 29; 11 (2): e0148764, 2016
114. Limentani, SA, Campone, M, Dorval, T, Curigliano G, de Boer, R, Vogel, C, White, S, Bachelot, T, Canon, JL, Disis, ML, Awada, A, Berliere, M, Amant, F, Levine, E, Burny, W, Callegaro, A, de Sousa Alves, PM, Louahed, J, Brichard, V, and Lehmann, FF: A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors, Breast Ca Res Treat, Apr;156(2):319-30, 2016.
115. Stanton, SE, Adams, S and Disis, ML: Variation in the incidence and magnitude of tumor infiltrating lymphocytes in breast cancer subtypes: A systemic review. JAMA Oncology, Oct 1;2(10):1354-1360. doi: 10.1001/jamaoncol.2016.1061.2016.
116. Stanton SE, Eary JE, Marzbani, EA, Mankoff, D, Salazar, SE, Higgins, D, Reichow, J, Dang Y and Disis ML: Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo. J Immunother of Ca, May 17:4:27, 2016.
117. Liao, J., Swensen, RE, Overnell, KJ, Hitchcock-Bernhardt, K, Reichow, JL, Childs, JS, Higgins, DM, Buening, BJ, Goff, BA, Morishima, C, and Disis, ML: Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator in recurrent platinum resistant ovarian cancer. (in press), Gynecologic Oncology, 2016.
118. Chow, LQM, Morishima, C, Eaton, KD, Baik, CS, Goulart, BH, Anderson, L, Manjarrez, KL, Dietch, GN, Bryan, JK, Hershberg, RM, Disis, ML, and Martins, RG. Phase 1b trial of the toll-like receptor 8 agonist, motolimod (VTX-2337), combined with cetuximab in patients with recurrent or metastatic squamous cell carcinomas of the head and neck. Clin Ca Res, 10.1158/1078-0432.CCR-16-1934 Published 3 November, 2016.

119. Pathangey LB, McCurry, DB, Gendler, SJ, Dominguez, AL, Gorman, J, Pathangey, G, Mihalik, LA, Dang, Y, Disis, ML, and Cohen, PA: Surrogate In vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. Oncotarget, Dec 11. doi: 10.18632/oncotarget.13911, 2016.
120. Cecil DL, Slota M, O'Meara MM, Curtis BC, Gad E, Dang Y, Herendeen D, Rastetter L, Disis ML. Immunization against HIF-1 α inhibits the growth of basal mammary tumors and targets mammary stem cells in vivo. Clin Cancer Res. Dec 30. pii: clincanres.1678.2016. doi: 10.1158/1078-0432.CCR-16-1678, 2016.
121. Salazar LG, Lu, H., Reichow, JL, Childs, JS, Coveler, AL, Higgins, DM, Waisman, J, Allison, KH, Dang Y, and Disis, ML: Topical Imiquimod and weekly Nab-paclitaxel for the treatment of breast cancer cutaneous metastases: A Phase II clinical trial. JAMA Oncology, January 19, doi:10.1001/jamaoncol.2016.6007, 2017.
122. Danaher, P, Warren, S, Dennis, L, D'Amico, L, White, A, Disis M.L., Geller, M, Odunsi, K, Beechem, J, and Fling, SP: Gene expression markers of tumor infiltrating lymphocytes. (in press), J Immunother of Ca, 2017.

B. Book Chapters:

1. Cheever, M.A., Chen, W., Disis, M.L., Takahashi, M. and Peace, D.J.: T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl. Specific Immunotherapy of Cancer with Vaccines, Drs. Bystry, Ferrone & Livingston (eds.) New York Academy of Sciences, pp. 101-112, 1993.
2. Cheever, M.A., Chen, W., Disis, M.L., and D.J. Peace: Overview of specific T cell therapy. Immunobiology of Renal Cell Carcinoma, Drs. Klein, Bukowski & Finke (eds.), Marcel Dekker, Inc., 1994.
3. Peace, D.J., Disis, M.L., Chen, W. and Cheever, M.A.: IL-2 in the induction and expansion of tumor specific immunity. In Cytokine-Induced Tumor Immunogenicity, G. Forni, R. Foa, A. Santoni, and L. Frati (eds.) Academic Press, 1994.
4. Disis, M.L., Bernhard, H., Gralow, J.R., Hand, S.L., Emery, S.R., Calenoff, E., and Cheever, M.A.: Immunity to the HER-2/neu oncogenic protein. Vaccines Against Virally Induced Cancers, Ciba Foundation Symposium, John Wiley & Sons, Inc., Baffins Lane, Chichester, U.K., 187: 198-211, 1994.
5. Disis, M.L. and Cheever, M.A.: HER-2/neu protein: A target for antigen specific immunotherapy of human cancer. Adv in Cancer Research, Vande Woude, G.F. and Klein, G. (Eds), Academic Press, San Diego, U.S.A., 71: 343-371, 1997.
6. Disis, M.L. and Cheever, M.A.: Clinical trials of HER-2/neu peptide based vaccines. Peptide-Based Cancer Vaccines, W. Martin Kast (Ed), Landes Bioscience, Georgetown, Texas, 24: 143-154, 2000.
7. Cheever, M.A. and Disis, M.L.: Immunology and immunotherapy of breast cancer. Diseases of the Breast, Harris, Lippman, Morrow and Osborne (Eds.), Lippincott, Philadelphia, PA, (2) 50: 811-824, 2000.
8. Schiffman, K. and Disis, M.L.: Update on vaccines for breast cancer. Diseases of the Breast Updates. Harris, J.R. and Lippman, M.E. (Eds.), Lippincott, Philadelphia, PA, (5) 2:1-14, 2002.
9. Salazar, L. and Disis, M.L.: Antibody responses to human tumor oncoproteins in cancer patients. Tumor antigens recognized by T cells and antibodies. H. Stauss and Y. Kawakami (Ed), Harwood Academic Publishers, 11: 172-190, 2002.
10. Knutson, K.L., Bishop, M.R., Schiffman, K., and Disis, M.L.: Immunotherapy for Breast Cancer. Cancer Chemotherapy and Biologic Response Modifiers- Annual 20. Editors: Giaccone, Schilsky and Sondel; Elsevier Science, 20:351-69, 2002.

11. Disis, M.L., Schiffman, K., Salazar, L.G., Almand, B., and Knutson, K.L.: HER-2/neu Vaccines. Cancer Chemotherapy and Biological Response Modifiers-Annual 21. Editors: Giaccone, Schilsky, and Sondel, Elsevier Science, 13:275-285, 2003.
12. Knutson KL, Curiel TJ, Salazar L, and Disis ML: Immunologic principles and immunotherapeutic approaches in ovarian cancer. Hematology/Oncology Clinics of North America. Ed.: Disis, M.L., WB Saunders, 17 (4): 1051-1073, 2003.
13. Disis, M.L. and Rivkin, S.: Future directions in the management of ovarian cancer. Hematology/Oncology Clinics of North America. Ed.: Disis, M.L., WB Saunders, 17 (4): 1075-1085, 2003.
14. Berger, C.M., Knutson, K.L., Salazar, L.G., Schiffman, K. and Disis, M.L.: Peptide-Based Vaccines. Handbook of Cancer Vaccines. Cancer Drug Discovery and Development, Morse, Clay and Lyerly (Eds), Humana Press, Totowa, NJ, 10: 121-135, 2004.
15. Disis, M.L., Schiffman, K., Salazar, L.G., and Knutson, K.L.: Antigen specific cancer vaccines. In: Perry MC, ed. ASCO Educational Book. Alexandria, VA: American Society of Clinical Oncology: 29-36, 2003.
16. Disis, M.L., Knutson, K.L., Salazar, L. G. and Schiffman K.: Immunology and immunotherapy of breast cancer. Diseases of the Breast, Harris, Lippman, Morrow and Osborne (Eds.), Lippincott, Philadelphia, PA., 2004.
17. Disis, M.L., Maeker, H.T., Clay, T.M., Lyerly, H.K., and Chang, J.C.C. Immunologic Monitoring to Assess Immunity to Solid Tumors in Measuring Immunity: The Immunologic Surrogates Handbook, First Edition" (eds) M.T. Lotze and A.W. Thomson. Academic Press, London, Chapter 40: 465-472, 2005.
18. Disis, M.L., Salazar, L.G., and Knutson, K.L.: Peptide based vaccines in breast cancer, in Immunology of Breast Cancer, Breast Disease, Ed. W.Z. Wei and D. Lopez, IOS Press, Amsterdam, The Netherlands, 15:1-9, 2004.
19. Wagner, W.M. and Disis, M.L.: Peptide vaccines for cancer treatment. The handbook of biologically active peptides, ed Kastin, A.J., Elsevier, Burlington, MA, 72, p 499-505, 2006.
20. Lai, V., Disis, M.L., and Lu, H.: Immune recognition of breast cancer. The Breast, Bland and Copeland (Eds), Saunders Elsevier, Philadelphia, PA., Chapter 33, p. 589-594, 2009.
21. V. Phan, D. Cecil, G. Holt, D. Herendeen, F. Kievit, M. Zhang, and M. L. Disis, Chapter 10, Epitope-based vaccines for cancer, in Cancer Vaccines: From Research to Clinical Practice, CRC Press, 2011.
22. Auci, DL, Cecil, DL, Herendeen, D, Broussard, EM, Liao, J, Holt, GE, and Disis, ML: Clinical application of plasmid based cancer vaccines. Gene Therapy of Cancer, 3rd Edition, Ed. E. Lattime and SL Gerson, Elsevier Science, San Diego, CA, 2013.
23. Disis, ML, Tarczy-Hornoch, P, and Ramsey BW: Increasing the efficiency and quality of clinical research with innovative services and informatics tools. Translational Medicine-What, Why, and How: an International Perspective, Ed. B. Alving, K. Dai, Karger AG, Vol 3, p. 89-97, 2012.
24. Bartek R.J., Disis, M.L., Weir, S.J. and the NCATS Working Group Members: NACTS Advisory Council Working Group on the IOM report: The CTSA program at NIH. 2014.
25. Stanton, S, Ramos E and Disis, ML: Immunologic approaches to breast cancer therapy. The Breast, Bland and Copeland (Eds), Saunders Elsevier, Philadelphia, PA. (in press), 2016.

C. Review Articles:

1. Disis M.L., Bernhard H., Gralow J.R., Hand S.L., Emery S.R., Calenoff E., Cheever M.A.: Immunity to the HER-2/neu oncogenic protein. Ciba Found Symp. 187: 198-207, 1994
2. Cheever, M.A., Disis, M.L., Bernhard, H., Gralow, J.R., Hand S.L., Huseby, E.S., Qin H.L., Takahashi, M. and Chen, W. Immunity to oncogenic proteins. Immunological Reviews. 145: 33-59, 1995.

3. Disis, M.L. and Cheever, M.A. Peptide vaccines for "self" tumor antigens. Peptides: Chemistry, Structure and Biology, Kaumaya, P.T.P. and Hodges, R.S. (Eds), Mayflower Scientific Ltd., Escom, Leiden, The Netherlands, 145: 752-754, 1995.
4. Disis, M.L. and Cheever, M.A.: Oncogenic proteins as tumor antigens. Current Opinion in Immunology, Alt, F. and Marrack, P. (Eds), Current Biology Ltd., London, U.K., (8) 5: 637-642, 1996.
5. Hand, S.L., Bernhard, H., Huseby, E.S., Rubin, W.D., Disis, M.L., and Cheever, M.A.: In vitro priming to tumor associated proteins. Advances in Experimental Med. Biol. 417: 503-509, 1997.
6. Disis, M.L. and Cheever, M.A.: HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res. 71: 343-71, 1997.
7. Disis, M.L. and Cheever, M.A.: HER-2/neu oncogenic protein: Issues in vaccine development. Critical Reviews in Immunology. 18:37-45, 1998.
8. Schoof, D.D., Smith, J.W., Disis, M.L., Brandt-Zawadski P., Wood, W., Doran, T., Johnson, E., and Urba, W.J.: Immunization of metastatic breast cancer patients with CD80-modified breast cancer cells and GM-CSF. Advances in Experimental Med. Biol. 451: 511-518, 1998.
9. Disis, M.L., McNeel, D.G., Schiffman, K.A., Rinn, K. and Knutson, K.L.: Peptide based tumor vaccines. Current Opinion in Oncologic, Endocrine, and Metabolic Drugs. 1(3): 253-259, 1999.
10. Knutson, K.L., Schiffman K., Rinn, K., and Disis, M.L.: Immunotherapeutic approaches to the treatment of breast cancer. J. Mammary Gland Biol. and Neoplasia, (4):4; 353-365, 1999.
11. McNeel, D.G. and Disis, M.L.: Tumor vaccines for the management of prostate cancer. Arch. Immunol. Ther. Exp., 48 (2); 85-93, 2000.
12. Disis, M.L., West, H.L., and Schiffman K.: Vaccines for the treatment and prevention of non-small cell lung cancer. Clin. Lung Cancer, 1 (4); 294-301, 2000.
13. Disis, M.L., Knutson, K.L., McNeel, D.G., Davis, D., and Schiffman, K.: Clinical translation of peptide based vaccine trials: the HER-2/neu model. Critical Reviews in Immunology, (21) 1-3; 263-273, 2001.
14. Disis, M.L. and Schiffman, K.: Cancer vaccines targeting the HER-2/neu oncogenic protein. Seminars in Oncology, Dec;28(6 Suppl 18):12-20, 2001.
15. Bernhard, H., Salazar, L., Schiffman, K., Smorlesi, A., Schmidt, B., Knutson, K.L., and Disis, M.L.: Vaccination against the HER-2/neu oncogenic protein. Endocrine Relat Cancer, Mar; 9(1):33-44, 2002.
16. Knutson, K.L. Almand, B., Mankoff, D.A., Schiffman, K., and Disis, M.L.: Adoptive T cell therapy for the treatment of solid tumors. Expert Opinion in Biological Therapy, Jan; 2 (1):55-66, 2002.
17. Keilholz, U., Weber, J., Finke, J., Gabilovich, D., Kast, M., Disis, M.L., Kirkwood, J., Scheibenbogen, C., Scholm, J., Maino, V., Lysterly, H.K., Lee, P., Storkus, W., Marincola, F., Worobec, A., and Atkins, M.B.: Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society of Biologic Therapy. J. of Immunotherapy, Mar-Apr; 25(2):97-138, 2002.
18. Disis, M.L.: Cancer vaccines targeting the HER-2/neu oncogenic protein, Biological Therapy of Breast Cancer, 4 (3):11-14, 2002.
19. Disis, M.L.: Immunologic targets for breast cancer therapy. Breast Disease, 15:83-90, 2002.
20. Knutson, K.L, Bishop, M.R., Schiffman, K. and Disis, M.L.: Immunotherapy for breast cancer. Cancer Chemother Biol Response Modif. 20: 351-69, 2002.
21. Walker, E.W. and Disis, M.L.: Monitoring immune responses in cancer patients receiving tumor vaccines. International Review of Immunology, 22:283-319, 2003.

22. Ko, B.K., Kawano, K., Murray, J.L., Disis, M.L., Efferson, C.L., Kuerer, H.M., Peoples, G.E., and Ioannides, C.G.: Clinical studies of vaccines targeting breast cancer. Clin. Cancer Res, (9): 3222-34, 2003.
23. Knutson, K.L., Curiel, T.J., Salazar, L., and Disis, M.L.: Immunologic principles and immunotherapeutic approaches in ovarian cancer. Hematol Oncol Clin North Am. 17(4): 1051-73, 2003.
24. Disis, M.L. and Rivkin, S.: Future directions in the management of ovarian cancer. Hematol Oncol Clin North Am. 17(4): 1075-85, 2003.
25. Disis, M.L., Schiffman, K., Salazar, L.G., Almand, B., and Knutson, K.L.: HER-2/neu vaccines. Cancer Chemother Biol Response Modif. 21: 275-85, 2003.
26. Disis, M.L.: The use of granulocyte macrophage colony stimulating factor as an adjuvant for breast cancer vaccines. Physicians Education Resource, Immune Enhancing Cytokines: 7-9, 2004.
27. Disis, M.L., Salazar, L.G., and Knutson, K.L.: Peptide-based vaccines in breast cancer. Breast Dis. 20: 3-11, 2004
28. Knutson, K.L. and Disis, M.L.: Augmenting T helper cell immunity in cancer. Curr Drug Targets Immune Endocr Metabol Disord, Dec, 5(4):365-371, 2005.
29. Knutson, K.L. and Disis, M.L.: Tumor antigen specific CD4+ T cells in cancer immunity and immunotherapy. Cancer Immunol Immunother., Aug; 54(8):721-8, 2005.
30. Knutson K.L., dela Rosa C., and Disis, M.L.: Laboratory analysis of T cell immunity, Frontiers in Biosciences, 11, 1932-1944, May 1, 2006.
31. Balkwill, F.R., Ashworth, A., Bast, R.C., Berek, J., Boyd, J., Disis, M.L., Gabra, H., Gore, M.E., Hamilton, T.C., Jacobs, I.J., Kaye, S.B., Kohn, E.C., Mills, G.B., and Urban, N.D.: 10th Biennial Helene Harris Memorial Trust Meeting. Cancer Research, 66: (6) March 15, 2904-2906, 2006.
32. Disis ML, Rivkin SE, Baron A, Markman M, Connolly D, Ueland F, Kohn E, Trimble E, and Berek JS. Progress in ovarian cancer research. Int J Gynecol Cancer. Mar-April; 16(2):463-9, 2006.
33. Knutson, K.L, Wagner, W., and Disis, M.L.: Adoptive T cell therapy of solid cancers. Cancer Immunol Immunother. 55(1): 96-103, 2006.
34. Swensen, R.E. and Disis, M.L.: Peptide based cancer vaccines. (in press) Current Cancer Drug Targets, 2007
35. Lu H, Goodell V, Disis ML. Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer. Expert Opin Ther Targets. Feb; 11(2):235-44, 2007.
36. Knutson KL, Disis ML, Salazar LG. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother. Mar; 56(3):271-85, 2007.
37. Holt, G.E., and Disis, M.L.; Immune modulation as a therapeutic strategy for non small cell lung cancer. Clin Lung Cancer, Feb; 9 Suppl 1:S13-9, 2008.
38. Cheever, M.A., Schlom, J., Weiner, L.M., Lyerly, H.K., Disis, M.L., Greenwood, A., Grad, O., and Nelson, W.G. for the Translational Research Working Group: Translational Research Working Group developmental pathway for immune response modifiers. Clin Ca Res, 14, September 15, 5692-5699, 2008.
39. Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, Hakansson L, Janetzki S, Kleen TO, Kirkwood J, Maccalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff CL Jr, Stroncek DF, Streicher H, Wu X, Zeskind B, Zhao Y, Zocca MB, Zwierzina H, and Marincola FM. A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on Immunotherapy Biomarkers". J Transl Med, Dec. 23; 6(1):81, 2008.
40. Disis, M.L., Jaffe, E.M., and Bernhard, H.: Cellular immune strategies for cancer therapy, Lancet, 373, February 21, 673-683, 2009.

41. Lai, V. and Disis, M.L.: Tumor-specific Th1 lymphocytes: Modulation of the tumor microenvironment to enhance cross-priming, American Association of Cancer Research Educational Book, 2009.
42. Coveler, A. and Disis, M.L.: Immunologic biomarkers to predict vaccine efficacy, American Association of Cancer Research Educational Book, 2009.
43. Dang, Y. and Disis, M.L.: Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer, Ann New York Academy of Sciences, Sep;1174:81-87, 2009.
44. Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L, Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H, Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CA, Streicher H, Stroncek DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkühle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB, and Marincola FM: Emerging concepts in biomarker discovery: The US-Japan workshop on immunologic molecular markers in oncology. J Translational Medicine. Jun 17;7(1);45, 2009.
45. Disis, ML and Park KH: Immunomodulation of breast cancer via tumor antigen specific Th1. Ca Res Treat. Sep;41(3):117-121, 2009.
46. Disis, ML: Immune regulation of cancer. J Clin Oncol, Oct 10;28(29):4531-8, 2010.
47. Coveler, A.L. Bates, N.E., and Disis, M.L.: Progress in the development of a therapeutic vaccine for breast cancer. Breast Cancer: Targets and therapy, 2; 25-36, 2010.
48. Butterfield, L.H., Disis, M.L., Khleif, S. and Marincola, F.: Immuno-oncology biomarkers 2010 and beyond. Journal of Trans Med, 8:130, 2010.
49. Disis, M.L.: Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother, 2011 Mar; 60(3):433-42. Epub 2011 Jan 8. Review. PMID: 21221967
50. O'Meara, M. and Disis, M.L.: Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: Emerging applications towards proof-of-concept. OMICS, Sept; 15(9):579-5788, 2011.
51. Butterfield, LH, Palucka, AK, Britten, CM, Dhodapkar, MV, Håkansson, L, Janetzki, S., Kawakami, Y, Kleen, TO, Lee, PP, Maccalli, C, Maecker, HT, Maino, VC, Maio, M, Malyguine, A, Masucci, G, Pawelec, G, Potter, DM, Rivoltini, LM, Salazar, LG, Schendel, DG, Slingluff, CL, Song, W, Stroncek, DF, Tahara, H, Thurin, M, Trinchieri, G., van Der Burg, SH, Whiteside, TL, Wigginton, JM, Marincola, FM, Fox, BA, and Disis, ML. Recommendations from the SCIT/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Ca Res, May 15; 17(10):3064-76, 2011.
52. Slota, M, Lim, J-B, Dang, Y, and Disis, ML: ELISPOT for measuring human immune responses to vaccines. Expert Rev Vaccines, 10(3), 299-306, 2011.
53. Bedognetti, D., Balwit, J.M., Wang, E., Disis, M.L., Britten, C.M., Delogu, L.G., Tomei, S., Fox, B.A., Gajewski, T.F., Marincola, F.M., and Butterfield, L.H.: SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools - a compass in the land of biomarker discovery. Journal of Translational Medicine, 9:155, 2011.
54. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Hakansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky

- HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Nelief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, and Disis ML. Defining the critical hurdles in cancer immunotherapy. J Trans Med. Dec. 14:9(1), 214, 2011.
55. Kelley, M, Edwards, K, Starks H, Fullerton, SM, James, R, Goering, S, Holland, S, Disis, ML, and Burke, W: Values in Translation: How asking the right questions can move translational science toward a greater health impact, Clin Trans Sci, 5: 445-451, 2012.
 56. CTSA Principal Investigators, Shamoon H, Center D, Davis P, Tuchman M, Ginsberg H, Califf R, Stephens D, Mellman T, Verbalis J, Nadler L, Shekhar A, Ford D, Rizza R, Shaker R, Brady K, Murphy B, Cronstein B, Hochman J, Greenland P, Orwoll E, Sinoway L, Greenberg H, Jackson R, Coller B, Topol E, Guay-Woodford L, Runge M, Clark R, McClain D, Selker H, Lowery C, Dubinett S, Berglund L, Cooper D, Firestein G, Johnston SC, Solway J, Heubi J, Sokol R, Nelson D, Tobacman L, Rosenthal G, Aaronson L, Barohn R, Kern P, Sullivan J, Shanley T, Blazar B, Larson R, FitzGerald G, Reis S, Pearson T, Buchanan T, McPherson D, Brasier A, Toto R, Disis M, Drezner M, Bernard G, Clore J, Evanoff B, Imperato-McGinley J, Sherwin R, Pulley J.: Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS). Clin Transl Sci., 2012 Apr; 5 (2):121-9. PMID: 22507116
 57. Disis, M.L.: Up close and personal with cancer. Science, 342: 1172, 2013.
 58. Liao, J.B. and Disis, M.L.: Therapeutic vaccines for ovarian cancer. Gynecologic Oncology, Sep; 130(3):667-73, 2013. Epub 2013 Jun 22. PMID: 23800697.
 59. Marzbani, E, Inatsuka, C., Lu, H., and Disis, M.L.: The Invisible arm of immunity in common cancer chemoprevention agents. Cancer Prevention Research, Aug; 6(8):764-73, 2013. PMID: 23918793
 60. Scott, C.S., Nagasawa, P., Disis, M.L., Ramsey, B.W., Martin, P., Abernathy, N., Hacker, B.M., and Schwartz H.: Expanding assessments of translational research programs: supplementing metrics with value judgment. Eval Health Prof. 2014 Mar; 37(1):83-97. Epub Sep 23, 2013. PMID: 24064429.
 61. Disis, M.L. and Stanton S.E.: Can immunity to breast cancer eliminate residual micrometastases? Clinical Cancer Research, Dec 1; 19(23):6398-403, 2013 PMID: 24298070
 62. Marquez JP, Stanton SE, and Disis, ML: The antigenic repertoire of pre-malignant and high risk lesions. Cancer Prev Res, Jan 8, 2015. PMID:25572327.
 63. Disis, M.L. and Palucka K.: Evaluation of cancer immunity in mice. Cold Spring Harb Protoc., Mar 1; 2014(3):231-4, 2014. PMID: 24173315
 64. Weber, J.S., Yang, J.C., Atkins, M.B. and Disis, M.L.: A review: The toxicities of immunotherapy for the practitioner. J Clin Oncol. Jun. 20; 33(18): 2092-9, 2015. PMID: 25918278.
 65. Disis, M.L.: Mechanism of action of immunotherapy. Semin Oncol. Oct;41 Suppl 5:S3-S1, 2014.
 66. Disis, ML and Stanton, SE: The role of immunity in triple negative breast cancer. American Society of Clinical Oncology Education Book, 2015.
 67. Stanton, S.E. and Disis, M.L.: Designing vaccines to prevent breast cancer recurrence or invasive disease. Immunotherapy. Feb; 7(2): 69-72, 2015.
 68. Cherryholmes, G, Stanton, S, and Disis, ML: Current methods of epitope identification for cancer vaccine design. Vaccine. Dec. 16; 33(51): 7408-14, 2015.

69. Weber, J.S., Yang, J.C., Atkins, M.B. and Disis, M.L.: Toxicities of immunotherapy for the practitioner. Journal of Clinical Oncology 33:2092-2099, 2015.
70. Kohrt HE, Tumei PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN). Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother of Cancer. Mar 15;4:15, 2016.
71. Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, Gilboa E, Hammond SA, Hershberg R, Korman AJ, Kvistborg P, Melief C, Mellman I, Palucka AK, Redchenko I, Robins H, Sallusto F, Schenkelberg T, Schoenberger S, Sosman J, Türeci Ö, Van den Eynde B, Koff W, Coukos G. The human vaccine project: A roadmap for cancer vaccine development. Sci Transl Med. 2016 Apr 13;8(334):334ps9.
72. Spira A, Disis ML, Schiller JT, Vilar E, Rebbeck TR, Bejar R, Ideker T, Arts J, Yurgelun MB, Mesirov JP, Rao A, Garber J, Jaffee EM, Lippman SM. Leveraging premalignant biology for immune-based cancer prevention. PNAS, Sep 27;113(39):10750-8, 2016.
73. Stanton SE and Disis ML: Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer, Oct 18; 4:59, 2016.
74. Watt WC, Cecil, DL and Disis ML. Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer. Seminars in Immunopath, Dec 14. 2016.
75. Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. Dec 1. doi: 10.1002/cncr.30449. 2016
76. Gwin WR, Standish, L, and Disis, ML. Use of the TLR2 ligand polysaccharide krestin to maximize conventional cancer therapy. (in press) Expert Reviews, 2017.
77. Disis, ML and Stanton, SE: Immunotherapy in breast cancer: An introduction. The Breast. (in press), 2017.

D. Editorials and Commentaries

1. Disis, M.L. and Schiffman, K.: Issues on Clinical Applications of Cancer Vaccines. J Immunother. 24(2): 104-105, 2001.
2. Disis, M.L. and Schiffman, K.: Issues on clinical application of cancer vaccines. J. Immunotherapy. 24(2): 104-105; 2001.
3. Schiffman, K and Disis, M.L.: Commentary: Endpoints of a Phase I Clinical Trial of Cancer Vaccines. Clin. Lung Cancer. 3 (1):58, 2001.
4. Knutson, K.L. and Disis, M.L.: Commentary: Towards a breast cancer vaccine: work in progress. Oncology. 17 (9): 1217-1218, 2003.
5. Kaufman, H.L. and Disis, M.L.: Immune system versus tumor: Shifting the balance in favor of dendritic cells and effective immunity. J. Clin. Invest., Mar;113 (5): 664-667, 2004.
6. Parks, M. R. and Disis, M.L.: Conflicts of interest in translational research. J. of Trans. Med., Aug 9; 2(1): 28, 2004.
7. Disis, M.L.: Immunotherapy of breast cancer-the time has come. Breast Diseases: A Year Book Quarterly, 2004.
8. Disis, M.L.: Molecular targeting with cancer vaccines. J. Clin Oncol, August 1 (23) 22: 4840-4841, 2005.
9. Salazar, L.G. and Disis, M.L.: Cancer vaccines: the role of tumor burden in tipping the scale towards vaccine efficacy. J. Clin Oncol, Oct 20; 23(30):7397-7398, 2005.

10. Disis, M.L.: Molecular targeting with cancer vaccines. J. Clin Oncol. August 1; 23(22): 4840-1, 2005.
11. Disis, ML and Lyerly, HK: The global role of the immune system in identifying cancer initiation and limiting disease progression. J Clin Oncol, Dec 10; 23 (35):8923-8925, 2005.
12. Salazar, L.G., and Disis, M.L.: Cancer vaccines: the role of tumor burden in tipping the scale toward vaccine efficacy. J. Clin Oncol. December 10; 23(35): 8923-5, 2005.
13. Disis, M.L, and Lyerly, H.K.: Global role of the immune system in identifying cancer initiation and limiting disease progression. J. Clin Oncol. Dec 10; 23(35): 8923-5, 2005.
14. Disis, ML: Translational oncology transforming cancer care. J Clin Oncol, Mar 1; 25 (7):750, 2007.
15. Lai, V.P. and Disis, M.L.: Tumor stromal barriers to the success of adoptive T cell therapy. Cancer Immunol Immunother, Feb; 57(2):281-283, 2008.
16. Disis, M.L.: Enhancing cancer vaccine efficacy via modulation of the tumor microenvironment. Clinical Cancer Research, Nov.1;15(21):6560-9, 2009.
17. Disis, M.L. and Slattery, J.T.: The road we must take: Multidisciplinary team science. Science Trans Med, March 10 (2) 22:22cm9, 2010.
18. Disis, M.L.: The ultimate in cancer chemoprevention: Cancer Vaccines. Ca Prevention Res, 3(4):406-409, 2010.
19. Verweij, J., Disis, M.L., and Cannistra, S.A.: Phase I studies of drug combinations. J. Clin. Oncol. Oct 10; 28(29):4531-9, 2010.
20. Disis, M.L., Schwartz, H.D., and Ramsey, B.W: Wouldn't we all like to be a little more LEAN? Clin Trans Sci, 3: 207–209. doi: 10.1111/j.1752-8062.2010.00224.x, 2010.
21. Broussard, E.K. and Disis, M.L.: TNM staging in colorectal cancer: T is for T cell and M is for memory. J Clin Oncol, Feb 20; 29(6):601-3, Epub 2011 Jan 18. PMID: 21245434
22. Disis, M.L., Watt, W.C., and Cecil D.L.: Th1 selection for clinically effective cancer vaccines. Immunooncology, Dec. 13; 3 (9):e954971, 2014.
23. Stanton SE and Disis, ML. Designing vaccines to prevent breast cancer recurrence or invasive disease. Immunotherapy, 7(2):69-72. doi: 10.2217/imt.15.5, 2015.
24. Butterfield, LH, Disis, ML, Fox, BA, Khleif, SN, and Marincola, FM: Preamble to the 2015 SITC immunotherapy biomarkers taskforce. Journal of the Immunotherapy of Cancer, Mar 24;3:8. doi: 10.1186/s40425-015-0052-6, 2015.
25. Disis M.L.: Adjuvant oophorectomy in the treatment of early-stage BRCA mutation-positive breast cancer. JAMA Oncology, Jun 1;1(3):313. doi: 10.1001/jamaoncol.2015.0708, 2015.
26. Disis, M.L.: The Lasker Awards: Highlighting the history of oncology. JAMA, 314(11):1123 doi:10.1001/jama.2015.10964, 2015.
27. Disis ML: Underlying autoimmune disease is not a contraindication to the use of ipilimumab, JAMA Oncol. Feb. 1; 2(2):241, 2016.

Submitted and Published Abstracts Presented at National Meetings:

Limited to the 3 most recent years.

1. Salazar LG, Lu H, Gray H, Higgins D, Childs J, Dang Y, Slota M, Parker S, Reichow J, Coveler AL, Disis ML: Final results of a phase II study of topical imiquimod and weekly abraxane in patients with breast cancer cutaneous metastases. CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), 2014
2. Disis ML, Coveler, AL, Higgins, D, Fintak, P, Waisman JR, Reichow, J, Slota,M, Childs, J, Dang, Y, and Salazar, LG: A phase I trial of the safety and immunogenicity of a DNA- based vaccine encoding the HER-2/neu (HER2) intracellular domain in subjects with HER2+ breast cancer. ASCO Annual Meeting, 2014
3. Disis, ML, Coveler, AL, Higgins, D, D'Amico, LA, Morishima, C, Waisman, JR, Reichow, J, Childs, J, Dang, Y, Marzbani E, and Salazar, LG: Phase I/II study of adoptive T cell therapy

- following in vivo priming with a HER-2/neu vaccine in patients with advanced stage HER2+ breast cancer. ASCO Annual Meeting, 2014.
4. Dao MD, Agnew KJ, Swisher EM, Goff BA, Disis ML, Liao JB. Serum antibodies recognizing hypoxia-inducible factor 1-alpha and platinum sensitivity in ovarian cancer. 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, 2014..
 5. Liao JB, Ovenell KJ, Wu M, Agnew KJ, Harrell MI, Swisher EM, Goff BA, Disis ML. Serum antibodies recognizing BRCA1 at time of diagnosis and primary platinum resistance in ovarian cancer. 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, 2014.
 6. Liao JB, Cecil DL, Reichow J, Higgins, D, Childs, J, Salazar, LG, and Disis, ML:. A phase I trial of a DNA plasmid based vaccine targeting insulin-like growth factor binding protein-2 (IGFBP-2) in patients with advanced ovarian cancer: preliminary safety and immunogenicity. 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, 2014.
 7. Hailing Lu, Gregory Diestch, Yi Yang, Mary Disis, and Robert Hershberg. TLR8 agonist VTX-2337 has the potential to decrease monocytic myeloid-derived suppressor cells. Unpublished, 2014.
 8. Disis, ML, Dang, Y, Salazar, LG, Reichow, J, Childs, J, Higgins, D, Stanton, SE. Immunotherapeutic approaches to breast cancer. San Antonio Breast Cancer Symposium, 2014.
 9. Cecil, D, Herendeen, D, Slota, M, Dang, Y, O'Meara, M, Gad, E, Rastetter, L, Koehnlein, M, Disis, ML. Vaccine Targeting HIF1A in Triple Negative Breast Cancer. Journal for Immuno Therapy of Cancer 2014, 2(Suppl 3):O5.
 10. Liao, JB, Reichow, J, Higgins, D, Childs, J, Salazar, LG, Disis, ML. Persistent immunity after therapeutic vaccination targeting HER2/neu correlated with post- vaccination magnitude of interferon gamma Elispot responses. Poster presentation at the 29th annual meeting of the Society for Immunotherapy of Cancer. November 6-9, 2014
 11. Stanton, SE, Gad, E, Marzbani, E, Rastetter, L, Disis, ML. Oral immunomodulatory agents prevent tumor growth and increase tumor CD8 T cell infiltrate; bexarotene further improves tumor response to conventional chemotherapy in breast tumors. San Antonio Breast Cancer Symposium, 2014.
 12. Disis, ML, Marquez, JP, Stanton, SE. Multi-antigen vaccines for cancer prevention. AACR Frontiers in Cancer Prevention Research, 2014.
 13. Morishima, C, McNeel, DG, Patel, MR, Kohrt, HEK, Waldmann, TA, Thompson, JA, Conlon, KC, Sondel, PM, Wakelee, HA, Disis, ML, Creekmore, SP, Miller, JS. CITN11-02 Interim Trial Results: Subcutaneous Administration of Recombinant Human IL-15 (rhIL-15) is Associated with Robust Expansion of Peripheral Blood CD56+ NK Cells. SITC 29th Annual Meeting, 2014.
 14. Stanton, SE, Reichow, J, Slota, M, Salazar, LG, Higgins, D, Childs, J, Disis, ML. Trastuzumab stimulates HER2 specific Type 1 immunity in HER2+ breast cancer patients. ASCO Annual Meeting 2015.
 15. Disis, ML, Patel, M, Pant, S, Infante, JR, Lockhart, AC, Kelly, K, Beck, J, Gordon, M, Weiss, G, Ejadi, S, Taylor, M, von Heydebreck, A, Chin, K, Cuillerot, JM, Gully, JJ. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-label expansion trial. ASCO Annual Meeting, 2015.
 16. Liao, JB, Swenson, RE, Reichow, J, Ovenell, KJ, Childs, J, Higgins, D, Buening, B, Goff, BA, Morishima, C, Disis, ML. Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator in recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer: clinical and immune responses. ASCO Annual Meeting, 2015.

17. Rutnam, ZJ, Dang, Y, Dietsch, G, Lu, H, Yang, Y, Hershberg, R, Disis, ML. TLR8 agonist VTX-2337 (motolimod) decreases monocytic myeloid-derived suppressor cells by inducing cell death. AACR Annual Meeting, 2015.
18. Marquez, JP, Broussard, EK, Rastetter, LR, Kim, R, Durazo, F, Ramos, E, Gad, E, Koehnlein, M, Coveler, A, Childs, J, Disis, ML. Multi-antigen vaccination for colon cancer treatment and prevention. ESMO, European Cancer Conference, 2015.
19. Disis, ML, Rastetter, LR, Gad, E, Koehnlein, M, Senter, PD, Gardai, S, Okeley, NM. Modulation of immunity with 2-Fluorofucose (2FF) for breast cancer treatment and prevention. SABCs, San Antonio, 2015.
20. Rengan, R, Bake, K, Salazar, L, Childs, J, Higgins, D, Redman, M, Reichow, J, Disis, ML. Overall Survival in Inflammatory Breast Cancer Patients Receiving HER-2/neu (HER2) Directed Vaccine Therapy: Matched Comparison with SEER Registry. SABCs, San Antonio, 2015.
21. Pujade Lauraine E, Colombo N, Disis ML, Fujiwara K, Ledermann J, Raza Mirza M, Richardson G, Beck T, Gaillard S, Haney P, Shneidman M, Morozov A, Monk B. Avelumab (MSB0010718C; anti-PD-L1) ± pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer: the phase 3 JAVELIN Ovarian 200 trial, ASCO, 2016
22. Disis ML, Patel M, Pant S, Hamilton E, Lockhart AC, Kelly K, Beck JT, Gordon M, Weiss GJ, Taylor M, Chaves J, Mita A, Chin K, von Heydebreck A, Cuillerot JM, Gulley JL. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase 1b trial: safety and clinical activity, ASCO, 2016
23. John B. Liao, Denise L. Cecil, Yushe Dang, Kelsey K. Baker, Kelsie J. Ovenell, Jessica Reichow, Stephanie Parker, Doreen M. Higgins, Jennifer S. Childs, Elizabeth K. Broussard, Andrew L. Coveler, Lupe G. Salazar, Barbara A. Goff, Mary W. Redman, Mary L. Disis. Vaccination targeting Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in advanced ovarian cancer: Safety and immunogenicity. ASCO, 2016
24. Stanton SE, Gad, E, Rastetter, L, and Disis ML: The retinoic acid receptor agonist bexarotene is expressed in antigen presenting cells and can activate type 1 antigen presenting cells. AACR, 2017.
25. Stanton SE, Ramos E, Annis, J, Timms, A, Rue, T, and Disis, ML: Identifying candidate antigens for a ductal carcinoma in situ vaccine that are essential breast cancer survival across multiple subtypes. AACR, 2017

Invited Lectureships:

Limited to the 3 most recent years

- | | |
|------|--|
| 2014 | Invited Speaker, AGA-Digestive Diseases Conference, Chicago, IL. |
| 2014 | Visiting Professor, MD Anderson, Houston, TX |
| 2014 | Invited Speaker, San Antonio Breast Cancer Conference, San Antonio, TX |
| 2015 | Invited Speaker, Breast Cancer Update, Loyola University, Chicago, IL |
| 2015 | Invited Speaker, St. Gallen Breast Meeting, Vienna, Austria |
| 2015 | Invited Speaker, AACR Annual Meeting, Philadelphia, PA |
| 2015 | Invited Speaker, ASCO Annual Meeting, Chicago, IL |
| 2015 | Invited Speaker, SITC Breast Cancer Immunology, Doha, Qatar |
| 2015 | Invited Speaker, Komen Foundation, Omaha, NE |

- 2015 Invited Speaker, Pezcoller Symposium, Trento, Italy
- 2015 Lubrano Lecture, Breast Cancer New Horizons Current Controversies, Boston, MA
- 2015 Invited Speaker, Cancer Institute of Puerto Rico, San Juan, Puerto Rico
- 2015 Invited Speaker, Lynn Sage Breast Meeting, Chicago, IL
- 2015 Invited Speaker and Session Chair, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- 2016 Invited Speaker, New York Metropolitan Breast Cancer Group, New York, NY
- 2016 Invited Speaker, Harvard University, Boston, MA
- 2016 Session Chair and Speaker, AACR Reimagining Cancer Prevention: A Roadmap for Science and Public Health, Leesberg, VA
- 2016 Keynote Speaker, UCSD Academic Industry Forum, San Diego, CA
- 2016 Invited Speaker, NABCG-BIG, Chicago, IL
- 2016 Invited Speaker, Annual Digestive Disease Meeting, San Diego, CA
- 2016 Keynote Address, Memorial University, BioMedicine Symposium, St. Johns, Newfoundland
- 2016 NCI Annual Advances in Cancer Prevention Lecture, Bethesda, MD
- 2016 Keynote Speaker, TBCRC Fall Meeting, Dallas, TX
- 2016 Invited Speaker, SITC 31st Annual Meeting, Washington, DC
- 2017 Invited Speaker, Cancer Center Grand Rounds, University of Wisconsin, Madison, WI
- 2017 Invited Speaker, Grand Rounds, Huntsman Cancer Center, Salt Lake City, UT
- 2017 Session Chair and Speaker, ESMO Immuno-Oncology Congress, Geneva, Switzerland
- 2017 Keynote Speaker, St. Gallen International Breast Cancer Conference, Vienna, Austria
- 2017 FCCC Distinguished Lecturer, Fox Chas Cancer Center, Philadelphia, PA
- 2017 Keynote Speaker, Global Breast Cancer Conference, Jeju Island, Korea
- 2017 Keynote Speaker, Taipei International Breast Cancer Symposium, Taipei, Taiwan